



Smith, S. A., Newby, A. C., & Bond, M. (2019). Ending restenosis: Inhibition of vascular smooth muscle cell proliferation by cAMP. *Cells*, 8(11), [1447]. <https://doi.org/10.3390/cells8111447>

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
[10.3390/cells8111447](https://doi.org/10.3390/cells8111447)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the final published version of the article (version of record). It first appeared online via MDPI at <https://www.mdpi.com/2073-4409/8/11/1447> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Review

Ending Restenosis: Inhibition of Vascular Smooth Muscle Cell Proliferation by cAMP

Sarah A. Smith, Andrew C. Newby and Mark Bond *

School of Translational Health Sciences, Faculty of Health Sciences, University of Bristol, Research Floor Level 7, Bristol Royal Infirmary, Bristol BS2 8HW, UK; S.Smith@bris.ac.uk (S.A.S.); A.Newby@bristol.ac.uk (A.C.N.)

* Correspondence: mark.bond@bris.ac.uk; Tel.: +44-117-3423586

Received: 24 October 2019; Accepted: 14 November 2019; Published: 16 November 2019



Abstract: Increased vascular smooth muscle cell (VSMC) proliferation contributes towards restenosis after angioplasty, vein graft intimal thickening and atherogenesis. The second messenger 3' 5' cyclic adenosine monophosphate (cAMP) plays an important role in maintaining VSMC quiescence in healthy vessels and repressing VSMC proliferation during resolution of vascular injury. Although the anti-mitogenic properties of cAMP in VSMC have been recognised for many years, it is only recently that we gained a detailed understanding of the underlying signalling mechanisms. Stimuli that elevate cAMP in VSMC inhibit G₁-S phase cell cycle progression by inhibiting expression of cyclins and preventing S-Phase Kinase Associated Protein-2 (Skp2-mediated degradation of cyclin-dependent kinase inhibitors. Early studies implicated inhibition of MAPK signalling, although this does not fully explain the anti-mitogenic effects of cAMP. The cAMP effectors, Protein Kinase A (PKA) and Exchange Protein Activated by cAMP (EPAC) act together to inhibit VSMC proliferation by inducing Cyclic-AMP Response Element Binding protein (CREB) activity and inhibiting members of the RhoGTPases, which results in remodelling of the actin cytoskeleton. Cyclic-AMP induced actin remodelling controls proliferation by modulating the activity of Serum Response Factor (SRF) and TEA Domain Transcription Factors (TEAD), which regulate expression of genes required for proliferation. Here we review recent research characterising these mechanisms, highlighting novel drug targets that may allow the anti-mitogenic properties of cAMP to be harnessed therapeutically to limit restenosis.

Keywords: cAMP; VSMC; proliferation; cell cycle; actin; cytoskeleton; SRF; TEAD; CREB

1. Introduction

Vascular responses to injury include development of atherosclerotic plaques in response to cardiovascular risk factors, restenotic lesions after angioplasty, or intima formation during late vein graft failure, all of which are associated with increased rates of vascular smooth muscle cell (VSMC) proliferation. Since its discovery in 1958 by Earl Sutherland, the second messenger 3' 5' cyclic adenosine monophosphate (cAMP) is implicated in diverse physiological processes, including in the cardiovascular system, where physiological signals that elevate intracellular cAMP levels control vascular smooth muscle cell proliferation as well as smooth muscle cell migration and differentiation, vasodilatation, endothelial permeability, cardiac chronotropic and ionotropic responses, and cardiac hypertrophy. The ability of cAMP signalling to antagonise VSMC proliferation contributes towards normal vascular development and homeostasis and limits intimal thickening in response to injury, offering the opportunity for pharmacological interventions at multiple levels. However, it is only recently that we are beginning to fully understand the underlying molecular mechanisms and therefore develop more selective therapies. Here we review recent advances in cAMP signalling research that shed light on these important mechanisms.

2. Importance of Vascular Smooth Muscle Cell (VSMC) Proliferation

Vascular smooth muscle cells (VSMC) are highly specialised cells that reside in the media layer of blood vessels where their primary function is to contract and relax to regulate vessel tone and blood pressure. In healthy vessels, these contractile or differentiated VSMC express abundant contractile cytoskeletal proteins, but exhibit extremely low proliferation rates [1,2]. Nevertheless, VSMC retain the ability to dramatically increase their rate of proliferation in response to vascular injury, to repair damage to the vessel wall [3]. Defects in this repair capacity, due to replicative senescence or increase apoptosis, is associated with medial thinning and aneurysm formation [4,5]. This capacity has no doubt evolved to compensate for traumatic injury, but its importance has recently become central in clinical cardiology and vascular surgery owing to its role in atherosclerosis and the two effective interventions developed to treat symptomatic atherosclerotic disease, angioplasty and venous by-pass graft surgery [6]. During atherosclerosis, medial VSMCs (or at least a small subpopulation of these) migrate to the developing lesion to generate a fibrous cap over lipid-rich lesions, which is believed to reduce the likelihood of thrombosis leading to myocardial, cerebral, renal and other tissue infarction [7,8]. The initial success of balloon angioplasty, often with metal stent implantation, in opening up vessels narrowed by atherosclerotic plaques is sometimes reversed owing to restenosis by expanded VSMCs and their associated connective tissue [9]. Likewise, vein by-pass grafts frequently fail thanks to growth of VSMC into a new occlusive intimal layer [10,11]. Proliferation of VSMC is believed to play a key role in both restenosis, where anti-proliferative agents reduce its frequency [12,13], and vein graft intima formation based on measurements of increased mitosis [14]. Hence targeting VSMC proliferation pharmacologically continues to be a clinically important goal.

The change in VSMC behaviour from contractile to proliferative is associated with a process termed phenotypic modulation [15], which *inter alia* is characterised by reduced expression of contractile proteins and increased expression of cell-cycle proteins that promote proliferation. Numerous signals are implicated in stimulating VSMC phenotypic modulation and increased VSMC proliferation, which are reviewed in detail elsewhere [16,17]. Briefly, this multi-step process includes inflammatory remodelling of the composition of the vascular extracellular matrix to one that promotes phenotypic modulation and is permissive to proliferation [18,19], and stimulation with VSMC mitogens such as platelet derived growth factors and fibroblast growth factors, which promote cell-cycle progression [20,21]. The primary purpose of VSMC proliferation is vascular repair after which it is essential that proliferation rates return to their normal low levels, an event that is associated with resolution of inflammation and re-establishment of normal endothelial function.

3. Anti-Mitogenic Effects of cAMP Signalling in VSMC

A large body of literature suggest that activation of cAMP signalling plays an important role in both the maintenance of VSMC quiescence in healthy vessels and the resolution of vascular repair mechanisms. The growth inhibitory properties of cAMP in cells of mesenchymal origin, which include VSMC, have been recognised for several decades [22], and this inhibitory effect is shared by many cells of other lineages. However, elevation of cAMP increases proliferation in embryonic stem cells [23], epithelial cells [24], endothelial cells [25,26], thyrocytes [27] and even VSMC under some conditions [28]. The mechanisms underlying this dichotomous behaviour have therefore sparked continuous interest, which is given greater impetus by the prospect it opens up for using cAMP elevation or some aspect of its downstream pathways to simultaneously decrease VSMC and increase EC proliferation, which should reduce the incidence of clinically evident restenosis without increasing the risk of endothelial denudation and hence late thrombosis.

One of the earliest reports documenting the anti-mitogenic effects of cAMP rather than cGMP in VSMC was in 1990, when Southgate et al. demonstrated that treatment of cultured rabbit aortic VSMC with the synthetic cAMP analogue 8-Bromoadenosine 3',5'-cyclic monophosphate (8Br-cAMP) inhibited serum mitogen-induced DNA synthesis [29]. Since then many studies confirmed these early findings. For example, incubation of cultured VSMC with other synthetic cAMP analogues,

including dibutyryl-cAMP [30–32], 8-Br-cAMP [33], 8-Chloro-cAMP [34] have similar growth inhibitory effects on VSMC in vitro. Furthermore, enhancing the rate of endogenous cAMP synthesis with the adenylyl cyclase activator, forskolin, or reducing the rate of cAMP degradation with phosphodiesterase inhibitors also strongly inhibits VSMC proliferation in vitro [25,31,32,35,36]. Consistent with the in vitro findings, treating vessels with these cAMP elevating agents in vivo results in inhibition of VSMC proliferation and intima formation in rodent models of vascular injury, importantly, without compromising endothelial integrity [32–34,37–41].

Synthesis of endogenous cAMP is balanced by cAMP hydrolysis, mediated by cyclic nucleotide phosphodiesterases (PDEs). In this way, PDE activity controls the amplitude, duration and compartmentalisation of cAMP signalling [42]. At least 60 different PDE isoenzymes encoded by 22 genes were described that together control intracellular levels of cAMP and cGMP. These are grouped into 11 families (PDE1–PDE11) based on their regulatory, kinetic and inhibitory properties [43–45], with different PDE displaying varying tissue specific expression and intracellular localisation patterns. Numerous studies demonstrated that PDE gene deletion or pharmacological PDE inhibition reduces VSMC proliferation in vitro and attenuates intima formation in vivo [35,36,38,46–48]. Depending on their phenotype, VSMC express PDE isoforms belonging to the PDE1, 3, 4 and 5 families [45]. Expression of *PDE1C* is low in quiescent contractile VSMC but elevated in synthetic VSMC in vitro and highly expressed in injury-induced neointimal VSMC of human coronary arteries. Importantly *PDE1C* gene deletion or pharmacological inhibition attenuated injury-induced VSMC proliferation and pathological vascular remodelling, consistent with a protective role of cyclic nucleotide signalling [49]. In synthetic VSMC, PDE1A is predominantly localised in the nucleus, compared to a cytoplasmic localisation in contractile VSMC. PDE1A activity has also been implicated promoting VSMC proliferation, in part through modulating levels of specific cell cycle regulatory proteins, including p27^{Kip1}, Cyclin-D and p53 [50]. Although PDE1 isoenzymes preferentially hydrolyse cGMP, at least some of the growth inhibitory functions of these PDEs were attributed to elevated levels of cAMP [31,49,51]. PDE represent the major cAMP-hydrolysing PDE expressed in VSMC. Genetic deletion of PDE3A, but not PDE3B, inhibits mitogen VSMC proliferation, indicating a selective role of this PDE3 isoform in cell cycle regulation in these cells [52]. This suggests that novel therapies targeting specific PDE isoform might be effective in ameliorating excessive VSMC proliferation and intima formation.

In searching for physiological cAMP elevating agents, early studies identified the metabolite adenosine as a potent inhibitor of VSMC proliferation [53–56]. Treatment of VSMC in vitro with adenosine or stable adenosine analogues potently inhibited serum mitogen-induced proliferation. Adenosine is produced via catabolism of adenosine triphosphate (ATP), which is released from injured VSMC [57], and is rapidly metabolised by membrane bound enzymes, including ecto-5'-nucleotidase, to produce extracellular adenosine [57]. Extracellular adenosine mediates its effects of VSMC via a family of four G-protein coupled adenosine receptors that are classified by their ability to either activate or inhibit adenylyl cyclase. A1 and A3 adenosine receptors are G₀ or G_i coupled and lead to increased intracellular Ca²⁺ ions or reductions in cAMP synthesis, respectively. By contrast, A2 receptor subtypes (A2A and A2B) are G_s coupled and their activation stimulates adenylyl cyclase activity and increases cAMP synthesis. Pharmacological studies using selective A2a or A2b receptor agonists and antagonists demonstrated that adenosine signalling through the A2B adenosine receptors inhibits of VSMC proliferation in vitro [25,54–56,58]. Moreover, A2B agonists reduce intima formation in rodent models of vascular injury in vivo [59]. These pharmacological effects may imply that activation of cAMP signalling in response to physiological stimuli such as adenosine that are present in the vessel wall play an important role in maintain VSMC in a quiescent contractile state in healthy vessels and limit excessive proliferation in response to vascular injury. Increased cAMP signalling is also likely to be important in promoting a return to quiescence as the healing process resolves. Consistent with this, inhibitory effects of A2BAR signalling on VSMC proliferation and intima formation were demonstrated using genetic studies where the A2BAR was knocked out [60] or silenced [61].

Prostacyclin production by the vascular endothelium represents another important physiological stimulus that represses VSMC proliferation by increasing cAMP levels in VSMC. Prostacyclin produced from a healthy endothelium by prostacyclin synthase binds to and activates the G_s coupled prostacyclin receptor (IP) on underlying VSMC to activate adenylyl cyclase and increase production of cAMP. Activation of IP receptors on VSMC using prostacyclin analogues potently inhibits VSMC proliferation [62–64], and intima formation in vivo [41,62,65,66], at least in part via adenylyl cyclase activation [67]. Consistent with these observations, genetic deletion of the prostacyclin receptor in mice is associated with exaggerated injury-induced vascular remodelling [68]. Endothelial dysfunction, which is often associated with a reduction in prostacyclin synthase expression [69], or injury-induced endothelial denudation dramatically reduces prostacyclin production within the vessel wall [70], thus removing this brake on VSMC proliferation. Conversely, regrowth of endothelium could help re-establish quiescence owing to restored prostacyclin production.

4. The Role of MAPK Signalling

Sustained activation of the p42/p44 MAPK kinase (ERK) pathway is a key step in mitogen-induced cell cycle progression [71]. Naturally, inhibition of MAPK signalling was one of the first mechanisms to be proposed to explain the anti-mitogenic effects of cAMP in cells of mesenchymal origin [72]. For example, early studies in fibroblasts and VSMC found that elevation of cAMP levels, either through addition of synthetic cAMP analogues, forskolin-activation of adenylyl cyclase, treatment with PDE inhibitors, or via stimulation of adenylyl cyclase with glucagon, cholera toxin or isoproterenol inhibited ERK activity induced by a range of mitogenic stimuli, including activation of receptor tyrosine kinases (RTK) (insulin, epidermal growth factor, platelet-derived growth factor [PDGF] isoforms), activation of GPCRs (lysophosphatidic acid (LPA)) or phorbol ester-mediated activation of protein kinase C (PKC) [73,74]. However, inhibition of p42/p44 ERK activation by cAMP is transient [75,76] and only partially reduces the sustained phase of ERK activation induced by some (e.g., PDGF_{BB}) but not all (e.g., bFGF) mitogens [74,77]. Hence, cAMP induces a temporal shift (delay) in mitogen stimulated MAPK signalling, although this alone could not account for the growth inhibitory action of cAMP [75,76]. Furthermore, several lines of evidence support the conclusion that the anti-mitogenic effects of cAMP can be dissociated from inhibition of ERKs [77]. For example, cAMP elevating agents retain the ability to strongly inhibit proliferation even when they are added several hours after growth factor induced ERK activity has peaked and returned to basal levels [77], whereas delayed addition of PD98059 an inhibitor of MEK, the kinase upstream of ERK, had no effect of proliferation. Finally, cAMP signalling can inhibit proliferation in cells in which MEK activity has already been inhibited with PD98059 [77]. Taken together, these studies suggest that the transient effects of cAMP on MAPK signalling at best only partially explains the anti-mitogenic properties of cAMP and implicate additional mechanisms.

5. Cell Cycle Inhibition by cAMP

Numerous studies show that cAMP inhibits VSMC proliferation by blocking progress from G_1 into S-phase of the cell cycle, where new DNA is synthesised [29,31,78–80]. For example, elevated cAMP reduces incorporation of thymidine analogues, such as tritiated thymidine or bromodeoxyuridine, indicating reduced DNA synthesis. The observation that cAMP retains the ability to inhibit proliferation even when addition of cAMP elevating agents is delayed by up to 12 hours after mitogen stimulation [77,81] implies its growth inhibitory properties are mediated, at least in part, by targeting events in the mid to late G_1 phase of the cell cycle. Progression from late- G_1 into S-phase is controlled at the G_1 -restriction point, which is centred on the retinoblastoma protein (Rb), which sequesters the E2F transcription factors that are needed for S-phase specific gene expression [82]. Hyper-phosphorylation of the Rb protein by cyclin-dependent kinases (CDK), particularly CDK4 and CDK2, represents the core regulatory mechanism controlling Rb inactivation. CDK activity is dependent on binding to their regulatory partners, the cyclins, levels of which fluctuate in synchrony with the cell cycle, owing to phases of synthesis and degradation. D-type cyclins, such as Cyclin-D₁

are the first cyclins to be synthesised following mitogen stimulation [71]. Cyclin-D:cdk4 complexes phosphorylate Rb, triggering E2F activation. Targets of E2F include Cyclin-E, Cyclin-A and many other S-phase specific genes. Thus, cyclin proteins control the timing of CDK activity (provided there is not an excess of inhibitors present) and therefore play an important role in regulating S-phase entry. Several studies demonstrated inhibition of cyclin protein production in response to cAMP elevating stimuli (see Figure 1). For example, stimulation of VSMC with the cAMP analogues, 8-Bromo-cAMP or dibutyryl-cAMP, reduced mitogen-induced cyclin-D₁ expression and inhibited activity of its catalytic partner, Cdk4 [78,79,83,84]. Similar effects have been reported for forskolin, which decreases PDGF_{BB} or serum mitogen-induced expression of cyclin-D₁ protein [77,78]. Inhibition of cyclin-D₁ levels likely occurs as a result of transcriptional inhibition, since both mRNA levels and cyclin-D₁ promoter activity are reduced by cAMP elevating stimuli [78,85]. This is mediated, at least in part, by repression of the transcription factor, c-myc [77,86], an important inducer of cyclin-D₁ gene expression [87]. Importantly, forced constitutive expression of either c-myc or cyclin-D₁ significantly reduces the growth inhibitory actions of cAMP, confirming the importance of this mechanism [88,89]. Cyclin-A expression has also been reported to be repressed by cAMP elevating stimuli [90]. Kamiya et al. [90] reported that cAMP analogues or forskolin inhibit cyclin-A gene transcription via a mechanism that is dependent on serine-133 phosphorylation of the cyclic-AMP response element binding protein (CREB) transcription factor, a post-translational modification typically associated with CREB activation. However, Kothapalli et al. [91] reported that the prostacyclin analogue, cicaprost, represses cyclin-A expression by reducing CREB binding to the cyclic-AMP response elements (CRE) in the cyclin-A promoter. Interestingly, treatment of VSMC with 8-Bromo-cAMP [84] or forskolin [78] did not inhibit expression of Cyclin-E, even though activity of the cyclin-E:cdk2 complex was inhibited. This may reflect the fact that cyclin-E can be expressed throughout the G₁ phase and that activity of the cyclin-E:cdk2 complex is typically regulated by levels of the cdk-inhibitors (CKIs), p21^{Cip1} and p27^{Kip1} [84,92]. These observations focus attention on the role of CKIs in the anti-mitogenic effects of cAMP.

In the early G₁ phase, cdk activity is subject to negative regulation by the Cip/Kip (p21^{Cip1}, p27^{Kip1} and p57^{Kip2}) and Ink (p15^{INK4a}, p16^{INK4b}, p18^{INK4c} and p19^{INK4d}) families of cyclin-dependent kinase inhibitors (CKIs) [93]. However, levels of p21^{Cip1} and p27^{Kip1} are typically down regulated in response to mitogen stimulation, effectively removing the brake on cdk activity. Numerous studies have demonstrated that cAMP elevating stimuli increase the levels of p21^{Cip1} and p27^{Kip1} in VSMC. For example, treatment of cultured VSMC with forskolin or cAMP analogues prevents mitogen-induced down-regulation of p27^{Kip1} [32,77,84,94] and p21^{Cip1} [95]. Similar increases in p27^{Kip1} and p21^{Cip1} are also observed in VSMC stimulated with GPCR agonists that elevate endogenous cAMP levels. For example, the prostacyclin mimetics Beraprost [41,96] or Cicaprost [97] significantly increase levels of p27^{Kip1} in VSMC. Unlike the cyclins, levels of CDKI mRNA remain relatively constant throughout the cell cycle. Instead, CDKI protein levels are typically controlled by rapid ubiquitin-dependent proteasomal-mediated degradation in response to mitogen stimulation [98,99]. This suggests that cAMP may inhibit proliferation by preventing the proteasomal degradation of CDKIs, effectively restraining the brake on proliferation. In 1999, the discovery of Skp2, an F-box protein component of the SCF^{skp2} ubiquitin ligase, responsible for p27^{Kip1} polyubiquitylation and degradation [100] ultimately provided a mechanistic link between cAMP and CDKI levels. Skp2 protein levels increase in late-G₁, triggering p27^{Kip1} and p21^{Cip1} degradation and cdk activation [100]. However, elevated cAMP completely blocks mitogen-induction of Skp2 [32,79], thereby explaining the effects of cAMP on CDKI levels. Moreover, forced expression of Skp2, rescues p27^{Kip1} and p21^{Cip1} down-regulation and Rb-hyper-phosphorylation in forskolin stimulated VSMC [79,101]. Skp2 overexpression also partially restores VSMC proliferation, suggesting that cAMP-induced down-regulation of Skp2 is a key mechanism contributing to cell cycle arrest in VSMC [79]. Exactly how cAMP controls Skp2 levels is unclear. Stimulation of VSMC with dibutyryl-cAMP reduces Skp2 protein levels at least in part by enhancing Skp2 protein turnover [32]. However, cAMP elevating stimuli also reduce Skp2 mRNA levels and activity of the Skp2 promoter, implicating transcriptional repression [32]. Skp2 mRNA

levels are low in differentiated VSMC that have very low rates of proliferation but are elevated in phenotypically modulated VSMC that proliferate rapidly in response to mitogens [79]. Lack of Skp2 gene expression in differentiated VSMC explains why these cells are unable to down-regulate p27^{Kip1} and proliferate, even when exposed to strong mitogenic stimulation [102]. Furthermore, transcriptional up-regulation of Skp2 during VSMC phenotypic modulation effectively primes these cells to be able to respond to mitogenic stimulation. Transcription of the Skp2 genes in proliferating VSMC is controlled by two closely related transcription factors, ZNF143 and ZNF76 [103]. However, it is not known if these are the targets for cAMP repression of Skp2 expression.




Figure 1. Cell cycle regulation by cAMP in VSMC. In VSMC, elevated cAMP inhibits S-phase entry. S-phase entry is controlled by retinoblastoma protein (Rb), which represses E2F-dependent gene expression. Rb inactivation requires phosphorylation by cdk enzymes, which are dependent on binding to cyclin proteins for catalytic activity. Expression of cyclin-A and -D is repressed by cAMP, via reductions in c-myc expression and activation of CREB respectively. Activity of cyclin:cdk complexes is inhibited by CDKIs, including p27^{Kip1} and p21^{Cip1}. Levels of p27^{Kip1} and p21^{Cip1} are reduced in late G₁ phase via Skp2-mediated ubiquitination and proteasomal degradation. Skp2 levels normally increase in late G₁ to remove this brake on cdk activity. However, cAMP represses induction of Skp2, which increases p27^{Kip1} and p21^{Cip1} levels. This reduction in cyclin expression and increase in CDKI levels, prevents phosphorylation of Rb and entry into S-phase.

6. The Role of cAMP Effectors

Several cAMP sensitive proteins are described, including protein kinase A (PKA), exchange protein activated by cAMP -1 and -2 (EPAC1/2), cyclic nucleotide gated ion channels (CNG) and the Popeye domain containing (Popdc) family of proteins.

Protein Kinase A, first discovered in 1968 [104], is one of the best studied members of the serine/threonine protein kinases. In an inactive state, PKA consists of two catalytic subunits and two regulatory subunits bound together as a tetrameric holoenzyme. Each regulatory subunit contains two

cAMP binding sites. The classical model of PKA activation involves binding of cAMP to the regulatory subunits, causing a change in conformation that results in dissociation and activation of the catalytic subunits that then phosphorylate their substrates [105]. However, some reports suggest that cAMP can activate PKA without catalytic subunit release [31,106–108] and that intact and active holoenzymes exist within the cytoplasm in the presence of cAMP. However, other studies suggest that a large molar excess of regulatory subunits over catalytic subunits is important for reducing catalytic subunit diffusion and increasing catalytic subunit recapture rate [109]. There are four PKA regulatory subunits (RI α , RII α , RI β and RII β) and three catalytic subunits (C α , C β and C γ). PKA regulatory subunits combine with different catalytic subunits to form various PKA isoforms that display different biochemical properties [110,111]. The four PKA regulatory subunits are structurally and functionally diverse; they display cell type specific expression patterns and different subcellular localisations [109,112–114], allowing for fine tuning of PKA activation and cellular responses. PKA holoenzymes interact with members of the A-kinase anchoring proteins (AKAPs) that tether PKA isoforms to distinct cellular locations in the vicinity of specific substrates. Studies using either pharmacological or peptide-based PKA inhibitors support a requirement for PKA activity in mediating the anti-mitogenic effects of cAMP [33,115–119]. Consistent with this, PKA inhibition reverses the inhibitory effects of cAMP elevating agents on neointima formation in a rat model of vascular injury [33]. It is important to note, however, that PKA activation has also been implicated in pro-mitogenic signalling in VSMC [28,120]. For example, PKA inhibition reduces VSMC proliferation induced by purinergic stimulation [28]. This likely reflects the importance of temporal regulation of PKA activation in determining cellular responses to cAMP elevating stimuli. Stimulation of purinergic receptors on VSMC results in a transient activation of PKA, which is essential for the proliferative response [28], which contrasts with the sustained activation of PKA induced by forskolin or prostacyclin analogues that inhibit VSMC proliferation [28]. However, sustained activation of PKA alone using a PKA selective cAMP analogue (6-BNZ-cAMP) does not significantly inhibit vascular [79] or airway smooth muscle cell proliferation [121], implying involvement of additional cAMP sensors in the anti-mitogenic response.

PKA has a wide repertoire of substrates that contain the consensus PKA phosphorylation sites based on Arg-Arg-X-Ser/Thr, Arg/Lys-C-C-Ser/Thr and Arg/Lys-X-Ser/Thr motifs [122]. Vasodilator-stimulated phosphoprotein (VASP) is a well characterised PKA substrate that is implicated in growth regulation. VASP is preferentially phosphorylated by PKG at serine239, whereas serine157 is the preferred phosphorylation site for PKA. In VSMC, VASP is associated with actin filaments, focal adhesions and cell-cell contacts, where it plays a role in regulating cell motility and proliferation [123]. Precisely how VASP phosphorylation at serine157 regulates VSMC proliferation is not clear. This residue can be phosphorylated in response to mitogen and phorbol ester stimulation, as well as in response to cAMP-mediated activation of PKA, in response to forskolin, cAMP analogues, ATP, endothelin or isoproterenol [28,79,124]. Ectopic expression of VASP containing a mutated PKA phosphorylation site (S157A) results in impaired mitogen stimulated proliferation, implying that phosphorylation at this site is required for VSMC proliferation [123]. This suggests that PKA-mediated phosphorylation of VASP may contribute towards the pro-mitogenic effects of transient PKA activation that occurs in response to purinergic stimulation [28] and not the anti-mitogenic effects of sustained PKA activation. Although PKA is generally accepted to represent the major serine/threonine kinase activated by cAMP, several studies have suggested that some of the biological effects of cAMP may, at least in part, be mediated via activation of Protein Kinase G (PKG) [32,125,126], which is classically activated by the second messenger cyclic guanosine monophosphate (cGMP). The cyclic nucleotide binding domain of PKG binds cGMP with higher affinity than cAMP. However, the intracellular concentrations of cAMP are typically higher than those of cGMP, suggesting that the selectivity of PKG for cGMP compared to cAMP is not controlled uniquely through affinities and cAMP can act as a partial PKG agonist [127].

Clearly, not all the biological effects of cAMP are mediated by PKA and PKG. The exchange proteins activated by cAMP (EPACs) were discovered while studying the mechanism of cAMP-mediated activation of Rap1 GTPase, which was insensitive to PKA inhibition [128]. A second study independently

identified EPACs by screening for brain enriched genes that containing cAMP binding motifs [129]. Two EPAC isoforms (EPAC1 and EPAC2) were described [129], both of which contain an N-terminal cAMP binding regulatory region and a C-terminal catalytic region responsible for guanine nucleotide exchange activity. EPAC1 has a single cyclic nucleotide binding domain while EPAC2 has two. Deletion of the N-terminal CNB domain(s) results in a fully active catalytic domain, suggesting a mechanism whereby the CNB auto-inhibits the catalytic domain [130]. A conformational change in the CNB induced by cAMP binding relieves the inhibition of the catalytic domain. Numerous studies have implicated EPAC-dependent signalling, either in parallel or independently of PKA, in the regulation of cell proliferation [40,79,121,131–148]. The effects of EPAC activation on cell proliferation is cell type specific, with growth inhibitory effects in VSMCs and some other cell types [79,131,134,149,150] and growth promoting effects in others, including endothelial cells [133,146,151]. Changes in the relative levels of cAMP sensors during vascular remodelling may contribute towards different functional responses. EPAC1 expression is increased following vascular injury in vivo, concomitantly with a decrease in PKA regulatory and catalytic subunit expression, implying a bias towards EPAC1 signalling following tissue injury that may be involved in promoting vascular repair [152]. However, its precise role in vascular remodelling may be complex. In isolated VSMC, selective EPAC activation alone using 8-(4-chloro-phenylthio)-2'-O-methyladenosine-3'-5'-cyclic monophosphate (8-pCPT-2'-O-Me-cAMP) or over expression of EPAC1 does not affect proliferation [79,152,153]. However, EPAC activation synergistically enhances the anti-mitogenic effects of selective PKA activation in VSMC in vitro [79]. Pharmacological EPAC activation reduces intima formation in an ex vivo human saphenous vein organ culture model [148] and EPAC1 gene deletion in mice promotes VSMC proliferation in vitro [154], consistent with an anti-mitogenic role of EPAC1 signalling. On the other hand, stimulation of ex vivo arterial organ cultures with 8-pCPT-2'-O-Me-cAMP or over expression of EPAC1 increases intimal thickening [152], whereas deletion of the EPAC1 gene in mice reduces intima formation and VSMC proliferation in wire-injured femoral arteries [154,155]. Moreover, pharmacological inhibition of EPAC with ESI-09 recapitulates the EPAC1 null phenotype and is sufficient to reduce intima formation [155]. These paradoxical effects of EPAC signalling on VSMC proliferation in vitro and intima formation in vivo may be at least partly explained by the ability of EPAC1 to enhance VSMC migration [152,153]. A further complication is that EPAC forms functionally compartmentalised signalling complexes with phosphodiesterase enzymes [121,122], which may be disrupted by EPAC1 gene deletion or silencing. Hence, data from these experiments needs to be interpreted cautiously.

Several mechanisms have been suggested to explain the positive and negative effects of EPAC1 on cell proliferation. Elevation of cAMP typically leads to the EPAC-dependent activation of Rap1, which has also been linked to both stimulatory and inhibitory effects on cell proliferation, depending on the cellular context. The Rap1b gene was originally identified by its ability to revert Ras-transformation [156]. Although the effector domains of Rap1b and Ras are almost identical, Rap1b is unable to activate Ras effector proteins, despite physically interacting with them [157–162]. In this model, Rap1b inhibits mitogenic signalling by antagonising Ras function. However, Rap1 has also been shown to have a mitogenic function in some cell types, typically those where cAMP is mitogenic [161,163,164].

Interestingly, EPAC-mediated activation of Rap1 does not appear to be involved in the anti-mitogenic effects of cAMP in VSMC. Evidence includes that selective activation of EPAC in VSMC does not inhibit proliferation despite rapid and robust Rap1 activation [79]. Furthermore, constitutively active mutants of Rap1 actually promote proliferation in VSMC [165] and inhibition of Rap1 activity by overexpression of Rap1GAP does not reverse cAMP-induced growth arrest [79]. This implicates other EPAC effectors, the identity of which are currently unknown. One possibility is that EPAC activation acts as a modulator of PKA signalling. For example, microarray analysis of VSMC stimulated with a selective EPAC agonist (8-pCPT-2'-O-Me-cAMP) for 8 h did not reveal any significantly regulated genes [139]. However, EPAC activation modulated expression of PKA-sensitive genes such as *Egr1* that plays a central role in the regulation of VSMC proliferation. Hence, EPAC signals converge with PKA signals to modulate expression of genes involved in cell proliferation.

Cyclic nucleotide gated ion channels are nonselective cation channels that open in response to direct binding of cAMP and cGMP. They are typically expressed in cone photoreceptor cells and olfactory sensory neurons [166], although they have also been detected in VSMC [167,168]. However, there is currently no evidence that CNG channels are involved in mediating the effects on cAMP on cell proliferation.

The Popdc proteins (Popdc1, Popdc2, Popdc3) are a family of integral membrane proteins that contain an extracellular N-terminal domain, three transmembrane domains and a cytosolic Popeye domain, which functions as a high affinity cAMP binding site [169]. Some downstream effects of binding of cAMP to Popdc proteins were described, including a dissociation of Popdc proteins from the cardiac two-pore potassium channel, TREK1, resulting in a reduction of the TREK-1 current [169]. There is currently no direct evidence that Popdc proteins play a role in the regulation of cell proliferation in response to cAMP elevating stimuli. However, Popdc proteins can interact with several proteins that are involved in mitogenic signalling. For example, Popdc1 physically interacts with guanine exchange factor T (GEFT), a guanine exchange factor (GEF) for Rho GTPases, including RhoA that play an important role in regulating actin polymerisation and mitogenic signalling [170]. In NIH3T3 fibroblasts, overexpression of GEFT promoted cell proliferation and migration [171]. Popdc proteins have also been implicated in modulation of the Wnt signalling pathway, which promotes transcription of genes required for VSMC proliferation [172–175]. Deletion of the Popdc1 gene results in increased Wnt activity, increased levels of β -catenin and enhanced expression of Wnt target genes, implying that Popdc1 represses Wnt/ β -catenin signalling [176]. Popdc1 knockout cells also display increased c-myc levels, due to the loss of Popdc1 mediated destruction of c-myc protein [176].

7. The Role of Actin Cytoskeleton Remodelling

Cyclic-AMP induced growth arrest in VSMC is associated with a profound but reversible change in cell morphology resulting from reorganisation of the actin cytoskeleton [32,79,94,177–181]. Stimulation of VSMC with forskolin, cAMP analogues or activation of the prostacyclin, adenosine A2B receptors or β -adrenergic receptors, results in a rapid acquisition of a ‘stellate’ morphology, characterised by a condensation of the cell body and formation of long branching processes. These changes were reported after as little as 10–15 min following stimulation, suggesting that they are an early event following cAMP elevation and occur independently of changes in gene expression [25,177]. Instead, these morphological changes are accompanied by loss of F-actin stress fibres and a decrease in the F:G actin ratio, indicating that cAMP inhibits actin polymerisation in VSMC [25]. Consistent with this, cAMP elevating stimuli inhibit the activity of members of the Rho GTPases (see Figure 2), including RhoA and Rac1 that play a central role in controlling actin polymerisation [94,177]. RhoGTPase inhibition appears to be a critical step since forced expression of constitutively active mutants of RhoA or Rac1 reverse cAMP-induced morphological changes, F-actin disassembly and inhibition of proliferation [94,182]. PKA can directly phosphorylate RhoA on Serine-188, a modification that terminates RhoA signalling by triggering translocation from the membrane to the cytosol, without affecting its ability to hydrolyse GTP [182]. However, cAMP elevating stimuli can also reduce levels of GTP bound RhoA, implying the existence of multiple mechanisms that control RhoGTPase function in response to cAMP. PKA can also directly phosphorylate G-actin, which reduces the rate of actin polymerisation [183]. Importantly, selective PKA activation with 6-BNZ-cAMP does not induce a strong stellate morphology or F-actin disassembly, implying that PKA-mediated phosphorylation of RhoA alone is insufficient [79]. Instead, simultaneous PKA and EPAC activation is necessary for these morphological changes and actin cytoskeleton remodelling. PKA and EPAC synergise to inhibit the activity of the RhoGTPase Rac1 [139], mirroring their synergistic action on growth arrest, but how EPAC cooperates with PKA to repress RhoGTPase activity is unclear. EPAC activity has also been linked to suppression of RhoA activity via the Rap1 effector proteins KRIT-1/CCM [184], Radil and Rasip1. Radil and Rasip1 inhibit RhoA activity via the RhoGAP, ArhGAP29 [185]. Taken together,

these observations suggest that PKA and EPAC signalling pathways converge at the level of Rho GTPase activity to modulate actin cytoskeleton dynamics.




Figure 2. Role of actin remodelling in cAMP-induced growth arrest. In VSMC, cAMP activates Protein Kinase A (PKA) and Exchange Protein Activated by cAMP (EPAC), which synergise to inhibit RhoGTPase activity. EPAC1 activation can contribute towards RhoGTPase inhibition via Rap1 mediated activation of Krit1, Radil and Rasip1. However, some studies suggest that EPAC1 inhibits actin polymerisation and proliferation via a Rap1-independent mechanism. Under low cAMP conditions, the F:G actin ratio is high, allowing Megakaryocytic Acute Leukemia Protein (MKL)-1 and -2 to translocate to the nucleus where they activate serum response factor (SRF)-dependent gene expression. Actin polymerisation also inhibits the Hippo kinases Mammalian Sterile20-like (MST) and Large Tumor Suppressor Kinase (LATS), allowing YAP and TAZ to translocate to the nucleus where they activate TEA Domain (TEAD) transcription factor dependent gene expression. Reduced actin polymerisation in response to elevated cAMP causes an increase in actin monomer levels and activation of MST and LATS. LATS-mediated phosphorylation of Yes-Associated Protein (YAP) and Transcriptional Co-Activator With PDZ-Binding Motif (TAZ) triggers their nuclear export. Actin monomer binds to Megakaryocytic Acute Leukemia Protein (MKL) -1 and -2 via their N-terminal RPEL domains, triggering their nuclear export. This results in a reduction in the expression of serum response factor (SRF) and TEAD-dependent gene expression required for cell proliferation.

Cell shape and actin cytoskeleton integrity is a critical regulator of cell proliferation in adhesion dependent cells. Studies using actin-binding drugs such as cytochalasin-D have revealed that actin cytoskeleton integrity is essential for cells to progress past the G₁-restriction point [186,187]. Early work focussed on impacts to the MAPK pathway [188,189], but using delayed addition of either cytochalasin-D or the MEK inhibitor PD98059 established that the ability of a properly organised actin cytoskeleton to promote cell cycle progression is not mediated simply via MAPK signalling. MAPK signalling is only essential in the early G₁ phase of the cell cycle whereas cytoskeleton integrity is essential throughout most of the G₁ phase, right up until the restriction point [187]. Clearly the effects of the actin cytoskeleton on proliferation can be dissociated from its effects on MAPK activity, much in the same way that the anti-mitogenic effects of cAMP signalling can be dissociated from effects on MAPK signalling [77], implying that loss of cytoskeletal integrity mediates the antiproliferative effects of cAMP.

Several lines of evidence confirm that RhoGTPase inhibition and a reduction in actin polymerisation underlie the anti-mitogenic effects of cAMP in VSMC. For example, forced expression of constitutively active mutants of RhoA (RhoAG14V) or Rac1 (Rac1G12V) reverse cAMP-induced morphological changes, restore actin polymerisation and rescue cell proliferation [94,177]. Genetic or pharmacological inhibition of RhoGTPase activity or direct disruption of actin polymerisation with cytochalasin-D, mimic cAMP-induced morphologic changes and inhibition of VSMC proliferation [94,139]. Cytochalasin-D or elevated cAMP also inhibit expression of actin-sensitive genes required for proliferation, including CCN1, CTGF and EGR1 [139,190]. Promoting actin polymerisation either with active RhoGTPase mutants or the actin-binding drug jasplakinolide rescues expression of these genes [139,190,191]. Finally, cAMP signalling is typically anti-mitogenic in cells where cAMP inhibits actin polymerisation e.g., VSMC [79,94,177] and fibroblasts [192], whereas, in endothelial cells, cAMP promotes formation of cortical actin stress fibres and does not inhibit proliferation [25,193,194].

The mechanisms linking actin cytoskeleton remodelling to changes in gene expression allow cells to sense and respond to various microenvironmental signals, including those that elevate cAMP. An important insight into these mechanisms came from studies analysing the regulation of the *c-fos* gene, which is controlled by binding of serum response factor (SRF) to a serum response element (SRE) in the *c-fos* promoter. Mitogen activation of MAPK signalling stimulates the *c-fos* promoter by inducing ternary complex factor (TCF) binding to SRF. However, promoter mutants incapable of binding TCFs remain responsive to signals that can activate Rho GTPase activity and induce cytoskeleton rearrangement [195,196]. Subsequent studies established that SRF activity is also sensitive to actin cytoskeleton dynamics, being inhibited by increases in monomeric actin [197]. The PKA substrate VASP is implicated in the regulation of actin polymerisation and VASP expression promotes SRF activity via a RhoA-dependent mechanism, suggesting that PKA-dependent phosphorylation of VASP is involved in the cAMP-mediated regulation of SRF [28,124,198–200]. Regulation of SRF activity in response to actin remodelling is mediated by the actin-binding SRF co-factors, Myocardin Related Transcription Factor A (MRTF-A/MKL1) and Myocardin Related Transcription Factor B MRTF-B/MKL2), which associate with G-actin via their N-terminal RPEL motifs (see Figure 2) [201]. Signals that activate Rho GTPases and promote actin polymerisation liberate MKL1 and MKL2 to translocate into the nucleus where they bind and activate SRF. Conversely, signals that inhibit actin polymerisation, enhance association of actin monomer with the MKL RPEL motifs, triggering their nuclear export and reduce expression of SRF-dependent immediate early genes. Consistent with this model, cAMP-induced actin remodelling in VSMC induces MKL1/2 nuclear export and inhibits MKL-SRF-dependent gene expression [25]. This mechanism accounts, at least in part, for the anti-mitotic effects of cAMP in VSMC, given that pharmacological or siRNA-mediated inhibition of MKL1 and -2 reduces VSMC proliferation in vitro [25] and genetic deletion of MKL1 reduces neointima formation in wire-injured femoral arteries in mice [202]. Interestingly, in endothelial cells, MKL1 remains constitutively nuclear, even after cAMP stimulation, a difference that likely reflects the maintenance of actin stress fibres and

low levels of actin monomer in endothelial cells and probably explains the divergent effects of cAMP signalling on proliferation in these two cell types.

The transcriptional coactivators Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) also play an important role in linking actin cytoskeleton dynamics to gene expression and changes in cell behaviour [203]. In the nucleus, YAP and TAZ interact with members of the TEA domain (TEAD) transcription factors and several other components of the transcriptional machinery, to regulate gene expression [204,205] and promote cell proliferation [206]. The functions of YAP and TAZ are negatively regulated by the Hippo pathway kinases MST and LATS [207,208]. LATS-mediated phosphorylation inactivates YAP and TAZ by triggering their nuclear exclusion and proteasomal degradation, leading to a reduction in TEAD-dependent gene expression [209,210]. This direct regulation of YAP and TAZ by LATS kinase is termed ‘canonical signalling’ in contrast to non-canonical LATS-independent mechanisms [211]. Recent studies showed that YAP and TAZ activity is sensitive to a wide range of environmental signals that modulate actin cytoskeleton dynamics and actin cytoskeleton tension, including extracellular matrix stiffness, adhesion, cell-cell contact, cell shape and G-protein-coupled receptor activation [212]. Actin polymerisation promotes YAP and TAZ nuclear localisation and TEAD activation either via inactivation of the Hippo kinases MST and LATS or via non-canonical pathways [211]. This results in a reduction in YAP and TAZ phosphorylation, permitting their nuclear accumulation where they drive cell proliferation [203,213,214]. Since cAMP elevating stimuli inhibit RhoGTPase activity and actin polymerisation [94,177], they rapidly induce YAP and TAZ phosphorylation, nuclear exclusion and reduced TEAD activity [94,191]. Moreover, silencing of YAP and TAZ inhibits VSMC proliferation in vitro and silencing or VSMC-specific deletion of YAP reduces neointimal formation in vivo [191,215,216], demonstrating their importance in VSMC proliferation. Constitutively active mutants of YAP and TAZ completely reverse cAMP-induced growth arrest, demonstrating that their inhibition contributes towards the anti-mitogenic effects of cAMP [191]. Analysis of the YAP induced transcriptome indicates that YAP-dependent activation of TEAD promotes cell proliferation by enhancing the expression of a wide range of proliferation associated genes [217], including CCN1 and CTGF that were implicated in VSMC proliferation [190,218] as well as key cell cycle regulators, such as Cyclin-D [215]. Interestingly, CCN1 and CTGF are also subject to regulation by the MKL-SRF axis [25], showing that genes required for efficient VSMC proliferation can be coupled to actin cytoskeleton organisation by both MKL-SRF and YAP/TAZ-TEAD transcriptional complexes. Genome wide analysis of TEAD transcription factor binding sites reveals that TEAD cooperates with other growth factor induced transcription factors to enhance the expression of cell cycle genes. For example, ChIP-seq analysis identifies extensive overlap in the genomic binding sites of TEAD with Myc and AP1 transcription factors [219,220], suggesting that these transcriptional complexes represent a site of integration of cAMP-induced actin remodelling and growth factor signalling.

8. The Role of CREB

Cyclic-AMP response element binding protein (CREB), a member of the leucine zipper family of transcription factors, was the first transcription factor shown to mediate gene expression in response to elevated cAMP [221]. In 1986, Marc Montminy and Richard Goodman described a cyclic-AMP response element (CRE) in the promoter region of the somatostatin gene that was essential for expression in response to cAMP [221]. Shortly after, they reported the identification of CREB as the transcription factor that bound to the CRE to mediate cAMP induction of the somatostatin gene [221]. Transcriptional activity of CREB was then shown to be dependent on PKA-mediated phosphorylation at serine-133 [222]. The CREB family of transcription factors consists of three members, CREB, CRE modulator (CREM) and activating transcription factor-1 (ATF-1) that can all mediate transcription via CREs. Each member contains a basic region/leucine zipper (bZIP) domain that allows homo- or hetero-dimerization with other bZIP family members [223]. CREB family members also contain a kinase-inducible domain, so named because it contains a cluster of phosphorylation sites including the regulatory serine-133

residue [224]. Phosphorylation of this serine enhances CREB-mediated transcription by promoting association of CREB with a co-activator called CREB binding protein (CBP) [224–226].

Several studies suggested that CREB contributes towards the anti-mitogenic effects of cAMP in VSMC (see Figure 3). For example, stimuli that elevate cAMP and inhibit VSMC proliferation are associated with increased CREB activity [47,91,205,227]. Inhibition of CREB using siRNA-mediated silencing or expression of dominant-negative CREB increases VSMC proliferation [228–230], whereas expression of constitutively active CREB mutants is inhibitory [47,228,230]. Furthermore, levels of CREB are reduced in response to a range of mitogenic stimuli and cardiovascular risk factors suggesting that CREB may play an important role in the maintenance of a normal quiescent VSMC phenotype [231]. For example, CREB levels are reduced in response to hypertension, aging, hyperlipidaemia [231] and diabetes [232] and correlate with the proliferative capacity of VSMC, being high in differentiated VSMC but reduced in phenotypically modulated cells [228]. These observations are consistent with a model where PKA-mediated phosphorylation of CREB in response to cAMP signalling inhibits VSMC proliferation. Loss of CREB in response to cardiovascular risk factors would remove this brake on proliferation and promote vascular remodelling [231]. However, many reports contradict this growth inhibitory role of CREB. Stimulation of VSMC with mitogens, including angiotensin II [233] or thrombin [234] or PDGF_{BB} [205], activates CREB; and proliferation induced by these mitogens is CREB-dependent. This suggests that CREB may be able to inhibit or promote proliferation depending on the activating stimulus or mechanism of CREB activation. Although phosphorylation at serine-133 is an important step in CREB activation, it is not always necessary or sufficient for CREB-dependent gene induction. CREB can be activated independently of serine-133 phosphorylation; and not all stimuli that induce serine-133 phosphorylation induce CREB activity. For example, expression of CREB target genes in the mouse hippocampus in response to fear conditioning is unaffected in transgenic mice expressing CREB with a mutated serine-133 residue (CREB S133A). Furthermore, using mouse embryonic fibroblasts from CREB S133A mice, Navqi et al. demonstrated that the requirement for serine-133 phosphorylation for the forskolin induction of CREB target genes was promoter specific [235]. On the other hand, T-cell receptor stimulation of Jurkat cells induces high levels of CREB serine-133 phosphorylation without inducing target gene expression. Also, induction of CREB activity by voltage-sensitive Ca²⁺ channels is markedly reduced in a PKA-deficient PC12 cells, despite robust CREB phosphorylation at serine-133. With respect to cAMP signalling, many reports demonstrated increased phosphorylation of CREB at serine-133 in response to cAMP elevation [222,235]. However, it should be noted that almost all of these studies induce CREB activity and phosphorylation with high concentrations (10–25 µM) of the adenylyl cyclase activator forskolin or high concentrations (>200 µM) of synthetic cAMP analogues, which induce supra-physiological levels of intracellular cAMP in VSMC [25]. Importantly, stimulation of VSMC with low concentrations of forskolin or physiological GPCR agonists induces robust activation of CREB without changing phosphorylation at serine-133 [205]. Instead, these physiological cAMP stimuli activate CREB by inducing nuclear translocation of two CREB co-factors, namely CREB Regulated Transcription Coactivators-2 and -3 (CRTC2 and CRTC3). The first two members of the CRTC family, consisting of CRTC1, CRTC2 and CRTC3, were identified in a genome screen for modulators of CREB activity [236]. Under basal conditions, CRTCs are sequestered in the cytoplasm through phosphorylation dependent interactions with 14-3-3 proteins [31]. In response to elevated cAMP or calcium signalling, CRTC dephosphorylation allows their translocation into the nucleus where they bind and activate CREB in a serine-133 independent mechanism [31]. In VSMC, physiological levels of cAMP, which do not increase CREB serine-133 phosphorylation, induce nuclear translocation of CRTC2 and CRTC3. This involves both PKA and EPAC, which cooperate to induce nuclear translocation of these CRTCs and activation of CREB [205]. How EPAC promotes CRTC activation is unknown but may involve activation of Ca²⁺ sensitive protein phosphatase 2B (calcineurin) [237], which promotes CRTC dephosphorylation and nuclear translocation [238]. Importantly, CRTC2 and CRTC3 are both essential and sufficient for cAMP-induced activation of CREB and inhibition of proliferation. This suggests that physiological

cAMP-induced CREB activity is mediated by nuclear translocation of CRTC2 and CRTC3 and occurs independently of changes in CREB serine 133 phosphorylation. In contrast, activation of CREB in response to VSMC mitogens, such as PDGF_{BB}, is associated with an increase in CREB serine-133 phosphorylation and occurs independently of CRTC nuclear translocation [205]. Importantly, CREB activity is essential for both the anti-mitogenic and mitogenic effects of these stimuli [205]. Taken together, it appears that different modes of CREB activation permit signal discrimination and allow CREB to regulate different subsets of target genes that in turn control diverse cellular responses.




Figure 3. The Role of CREB in the regulation of VSMC proliferation. Elevated levels of cAMP activate Protein Kinase A (PKA) and Exchange Protein Activated by cAMP (EPAC), which synergise to increase Cyclic-AMP Response Element Binding Protein (CREB)-dependent gene expression. High levels of cAMP increase CREB phosphorylation at serine-133, although low physiological levels of cAMP can induce CREB activity without increasing phosphorylation at serine-133. Cyclic-AMP stimulates nuclear translocation of the CREB regulated transcription coactivators CRTC2 and CRTC-3, which bind and activate CREB. CRTC-mediated CREB activation represses VSMC proliferation. CREB activity can also be increased in response to mitogen stimulation. This is associated with increased phosphorylation at serine-133 that can be mediated by MSK1/2 kinase, but not nuclear translocation of CRTC proteins. Activation of CREB in this way is required for maximal proliferation. Hence CREB can promote or inhibit proliferation depending on the mode of activation.

9. Future Pharmacological and Clinical Implications

It is only after three decades of research that we are beginning to understand the complex cAMP signalling mechanisms that control VSMC proliferation. The focus now should be translating this

knowledge into useful clinical therapies. This detailed knowledge has identified several potential new drug targets that may allow the vascular protective properties of cAMP to be harnessed therapeutically, while avoiding the unwanted or off target effects associated with directly targeting cAMP levels. The RhoA-ROCK pathway and remodelling of the actin cytoskeleton undoubtedly plays a central role in mediating the growth inhibitory effects of cAMP in VSMC and represents an attractive drug target. ROCK inhibitors such as Fasudil and Y27632 are available and were shown to inhibit VSMC proliferation in vitro and limit arterial injury-induced intima formation in vivo [239], while permitting endothelial regrowth [240]. This cell type specific inhibition of proliferation is an advantage over current generations of anti-mitotics used in drug eluting stents.

Other potential drug targets include the transcriptional co-factors that mediate the anti-mitogenic effects of cAMP, including MKL1/2, YAP/TAZ and the CRTC. Although transcription factor complexes are often believed to be challenging drug targets, recent research suggest that these transcription factor:co-factor complexes may be amenable to pharmacological manipulation. Small molecule inhibitors (e.g., CCG1423) are available that block nuclear translocation of MKL1/2 into the nucleus [241], mimicking the effects of cAMP in VSMC [25]. These inhibitors reduce MKL-SRF-dependent gene expression, VSMC proliferation and injury-induced intima formation in vivo [202]. Several small molecules have also been described that disrupt interaction of the YAP and TAZ co-factors with TEAD transcription factors [242–247] that also inhibit VSMC proliferation.

10. Concluding Remarks

We are beginning to understand that remodelling of the actin cytoskeleton plays a central role in the complex cAMP signalling mechanisms that control VSMC proliferation. Indeed, actin cytoskeleton organisation is promoted by a diverse set of signals from the local microenvironment, including growth factors, inflammatory cytokines, the composition and mechanical properties of the ECM, and mitogenic GPCR ligands. The convergence of these signals at the cytoskeleton allows cells to generate appropriate cellular responses to multiple cues from the local environment. Moreover, through actin de-polymerisation, cAMP antagonises cellular responses to mitogenic stimuli, which is important for the maintenance of VSMC quiescence in healthy vessels and controlling resolution of repair processes following vascular insult or injury. Conversely cytoplasmic to nuclear translocation of transcriptional regulators by mitogenic factors and cAMP is a key mechanism by which signals from the plasma membrane are rapidly transduced into the nucleus. Further research into these mechanisms and the way they differ between different cell types, e.g., VSMC and endothelial cells, should lead to valuable pharmacological targets for vascular and other pathologies.

Author Contributions: S.A.S, A.C.N. and M.B. all contributed to the preparation of this manuscript.

Funding: This research was funded by the British Heart Foundation, grant number PG/15/100/31877 and the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Campbell, J.H.; Campbell, G.R. Endothelial-cell influences on vascular smooth-muscle phenotype. *Annu. Rev. Physiol.* **1986**, *48*, 295–306. [[CrossRef](#)]
2. Gordon, D.; Schwartz, S.M. Replication of arterial smooth-muscle cells in hypertension and atherosclerosis. *Am. J. Cardiol.* **1987**, *59*, A44–A48. [[CrossRef](#)]
3. Ross, R. The pathogenesis of atherosclerosis - an update. *N. Engl. J. Med.* **1986**, *314*, 488–500. [[CrossRef](#)]
4. Blunder, S.; Messner, B.; Aschacher, T.; Zeller, I.; Turkcan, A.; Wiedemann, D.; Andreas, M.; Bluschke, G.; Laufer, G.; Schachner, T.; et al. Characteristics of TAV- and BAV-associated thoracic aortic aneurysms—Smooth muscle cell biology, expression profiling, and histological analyses. *Atherosclerosis* **2012**, *220*, 355–361. [[CrossRef](#)]

5. Aschacher, T.; Salameh, O.; Enzmann, F.; Messner, B.; Bergmann, M. Telomere Biology and Thoracic Aortic Aneurysm. *Int. J. Mol. Sci.* **2018**, *19*. [[CrossRef](#)]
6. Bennett, M.R.; Sinha, S.; Owens, G.K. Vascular Smooth Muscle Cells in Atherosclerosis. *Circ. Res.* **2016**, *118*, 692–702. [[CrossRef](#)]
7. Newby, A.; Zaltsman, A. Fibrous cap formation or destruction - the critical importance of vascular smooth muscle cell proliferation and matrix formation. *Cardiovasc. Res.* **1999**, *41*, 345–360. [[CrossRef](#)]
8. Jacobsen, K.; Lund, M.B.; Shim, J.; Gunnarsen, S.; Fichtbauer, E.M.; Kjolby, M.; Carramolino, L.; Bentzon, J.F. Diverse cellular architecture of atherosclerotic plaque derives from clonal expansion of a few medial SMCs. *Jci Insight* **2017**, *2*. [[CrossRef](#)]
9. Marx, S.O.; Totary-Jain, H.; Marks, A.R. Vascular Smooth Muscle Cell Proliferation in Restenosis. *Circ. Cardiovasc. Interv.* **2011**, *4*, 104–111. [[CrossRef](#)]
10. Shukla, N.; Jeremy, J.Y. Pathophysiology of saphenous vein graft failure: A brief overview of interventions. *Curr. Opin. Pharmacol.* **2012**, *12*, 114–120. [[CrossRef](#)]
11. Wadey, K.; Lopes, J.; Bendeck, M.; George, S. Role of smooth muscle cells in coronary artery bypass grafting failure. *Cardiovasc. Res.* **2018**, *114*, 601–610. [[CrossRef](#)]
12. Sousa, J.E.; Costa, M.A.; Abizaid, A.; Abizaid, A.S.; Feres, F.; Pinto, I.M.F.; Seixas, A.C.; Staico, R.; Mattos, L.A.; Sousa, A.; et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries - A quantitative coronary angiography and three-dimensional intravascular ultrasound study. *Circulation* **2001**, *103*, 192–195. [[CrossRef](#)]
13. Morice, M.; Serruys, P.W.; Sousa, J.E.; Fajadet, J.; Hayashi, E.B.; Perin, M.; Colombo, A.; Schuler, G.; Barragan, P.; Guagliumi, G.; et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N. Engl. J. Med.* **2002**, *346*, 1773–1780. [[CrossRef](#)]
14. Kenagy, R.D.; Fukai, N.; Min, S.K.; Jalikis, F.; Kohler, T.R.; Clowes, A.W. Proliferative capacity of vein graft smooth muscle cells and fibroblasts in vitro correlates with graft stenosis. *J. Vasc. Surg.* **2009**, *49*, 1282–1288. [[CrossRef](#)]
15. Campbell, G.R.; Chamleycampbell, J.H. Smooth-muscle phenotypic modulation - role in atherogenesis. *Med. Hypotheses* **1981**, *7*, 729–735. [[CrossRef](#)]
16. Owens, G.K.; Kumar, M.; Wamhoff, B. Molecular Regulation of Vascular Smooth Muscle Cell Differentiation in Development and Disease. *Physiol. Rev.* **2003**, *84*, 767–801. [[CrossRef](#)]
17. Hedin, U.; Roy, J.; Tran, P.K. Control of smooth muscle cell proliferation in vascular disease. *Curr. Opin. Cell Biol.* **2004**, *15*, 559–565. [[CrossRef](#)]
18. Hedin, U.; Bottger, B.; Forsberg, E.; Johansson, S.; Thyberg, J. Diverse effects of fibronectin and laminin on phenotypic properties of cultured arterial smooth muscle cells. *J. Cell. Biol.* **1988**, *107*, 307–319. [[CrossRef](#)]
19. Newby, A. Matrix metalloproteinases regulated migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. *Cardiovasc. Res.* **2006**, *69*, 614–624. [[CrossRef](#)]
20. Lindner, V.; Lappi, D.; Baird, A.; Majack, R.; Reidy, M. Role of basic fibroblast growth factor in vascular lesion formation. *Circ. Res.* **1991**, *68*, 106–113. [[CrossRef](#)]
21. Ross, R.; Vogel, A. Platelet-derived growth factor. *Cell* **1978**, *14*, 203–210. [[CrossRef](#)]
22. Pastan, I.; Johnson, G.; Anderson, W. Role of cyclic nucleotides in growth control. *Annu. Rev. Biochem.* **1975**, *44*, 491–522. [[CrossRef](#)]
23. Kim, M.O.; Lee, Y.J.; Park, J.H.; Ryu, J.M.; Yun, S.P.; Han, H.J. PKA and cAMP stimulate proliferation of mouse embryonic stem cells by elevating GLUT1 expression mediated by the NF-kappa B and CREB/CBP signaling pathways. *Biochim. Biophys. Acta-Gen. Subj.* **2012**, *1820*, 1636–1646. [[CrossRef](#)]
24. Yamaguchi, T.; Nagao, S.; Wallace, D.P.; Belibi, F.A.; Cowley, B.D.; Pelling, J.C.; Grantham, J.J. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. *Kidney Int.* **2003**, *63*, 1983–1994. [[CrossRef](#)] [[PubMed](#)]
25. Smith, M.C.; Hudson, C.A.; Kimura, T.E.; White, S.J.; Sala-Newby, G.B.; Newby, A.C.; Bond, M. Divergent Regulation of Actin Dynamics and Megakaryoblastic Leukemia-1 and-2 (Mkl1/2) by cAMP in Endothelial and Smooth Muscle Cells. *Sci. Rep.* **2017**, *7*, 13. [[CrossRef](#)]
26. Meininger, C.J.; Granger, H.J. Mechanisms leading to adenosine-stimulated proliferation of microvascular endothelial-cells. *Am. J. Physiol.* **1990**, *258*, H198–H206. [[CrossRef](#)]
27. Garcia-Jimenez, C.; Santisteban, P. Thyroid-stimulating hormone/cAMP-mediated proliferation in thyrocytes. *Expert Rev. Endocrinol. Metab.* **2014**, *3*, 473–491. [[CrossRef](#)]

28. Hogarth, D.K.; Sandbo, N.; Taurin, S.; Kolenko, V.; Miano, J.M.; Dulin, N.O. Dual role of PKA in phenotypic modulation of vascular smooth muscle cells by extracellular ATP. *Am. J. Physiol.-Cell Physiol.* **2004**, *287*, C449–C456. [\[CrossRef\]](#)
29. Southgate, K.; AC, N. Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP. *Atherosclerosis* **1990**, *82*, 113–123. [\[CrossRef\]](#)
30. Sadhu, D.N.; Ramos, K.S. Cyclic-AMP inhibits C-HA-RAS protooncogene expression and DNA-synthesis in rat aortic smooth-muscle cells. *Experientia* **1993**, *49*, 567–570. [\[CrossRef\]](#)
31. Bittinger, M.A.; McWhinnie, E.; Meltzer, J.; Iourgenko, V.; Latario, B.; Liu, X.L.; Chen, C.H.; Song, C.Z.; Garza, D.; Labow, M. Activation of cAMP response element-mediated gene expression by regulated nuclear transport of TORC proteins. *Curr. Biol.* **2004**, *14*, 2156–2161. [\[CrossRef\]](#)
32. Wu, Y.; Bond, M.; Sala-Newby, G.; Newby, A. Altered S-phase kinase-associated protein-2 levels are a major mediator of cyclic nucleotide-induced inhibition of vascular smooth muscle cell proliferation. *Circ. Res.* **2006**, *98*, 1141–1150. [\[CrossRef\]](#)
33. Indolfi, C.; Avvedimento, E.V.; DiLorenzo, E.; Esposito, G.; Rapacciuolo, A.; Giuliano, P.; Grieco, D.; Cavuto, L.; Stingone, A.M.; Ciullo, I.; et al. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. *Nat. Med.* **1997**, *3*, 775–779. [\[CrossRef\]](#)
34. Indolfi, C.; Di Lorenzo, E.; Rapacciuolo, A.; Stingone, A.M.; Stabile, E.; Leccia, A.; Torella, D.; Caputo, R.; Ciardiello, F.; Tortora, G.; et al. 8-chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo. *J. Am. Coll. Cardiol.* **2000**, *36*, 288–293. [\[CrossRef\]](#)
35. Souness, J.E.; Hassall, G.A.; Parrott, D.P. Inhibition of pig aortic smooth-muscle cell-DNA synthesis by selective type-III and type-IV cyclic-AMP phosphodiesterase inhibitors. *Biochem. Pharmacol.* **1992**, *44*, 857–866. [\[CrossRef\]](#)
36. Pan, X.L.; Arauz, E.; Krzanowski, J.J.; Fitzpatrick, D.F.; Polson, J.B. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE-III and PDE-IV to attenuate proliferation of rat vascular smooth-muscle cells. *Biochem. Pharmacol.* **1994**, *48*, 827–835. [\[CrossRef\]](#)
37. Inoue, Y.; Toga, K.; Sudo, T.; Tachibana, K.; Tochizawa, S.; Kimura, Y.; Yoshida, Y.; Hidaka, H. Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model. *Br. J. Pharmacol.* **2000**, *130*, 231–241. [\[CrossRef\]](#)
38. Kondo, K.; Umemura, K.; Miyaji, M.; Nakashima, M. Milrinone, a phosphodiesterase inhibitor, suppresses intimal thickening after photochemically induced endothelial injury in the mouse femoral artery. *Atherosclerosis* **1999**, *142*, 133–138. [\[CrossRef\]](#)
39. Fujinaga, K.; Onoda, K.; Yamamoto, K.; Imanaka-Yoshida, K.; Takao, M.; Shimono, T.; Shimpō, H.; Yoshida, T.; Yada, I. Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-c synthesis and smooth muscle cell proliferation in free artery grafts. *J. Thorac. Cardiovasc. Surg.* **2004**, *128*, 357–363. [\[CrossRef\]](#)
40. Lehrke, M.; Kahles, F.; Makowska, A.; Tilstam, P.V.; Diebold, S.; Marx, J.; Stohr, R.; Hess, K.; Endorf, E.B.; Bruemmer, D.; et al. PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner. *J. Mol. Cell. Cardiol.* **2015**, *81*, 23–33. [\[CrossRef\]](#)
41. Ii, M.; Hoshiga, M.; Fukui, R.; Negoro, N.; Nakakoji, T.; Nishiguchi, F.; Kohbayashi, E.; Ishihara, T.; Hanafusa, T. Beraprost sodium regulates cell cycle in vascular smooth muscle cells through cAMP signaling by preventing down-regulation of p27(Kip1). *Cardiovasc. Res.* **2001**, *52*, 500–508. [\[CrossRef\]](#)
42. Brescia, M.; Zaccolo, M. Modulation of Compartmentalised Cyclic Nucleotide Signalling via Local Inhibition of Phosphodiesterase Activity. *Int. J. Mol. Sci.* **2016**, *17*, 11. [\[CrossRef\]](#)
43. Beavo, J.A. Cyclic-nucleotide phosphodiesterases - functional implications of multiple isoforms. *Physiol. Rev.* **1995**, *75*, 725–748. [\[CrossRef\]](#) [\[PubMed\]](#)
44. Baillie, G.S.; Tejada, G.S.; Kelly, M.P. Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: Inhibition and beyond. *Nat. Rev. Drug Discov.* **2019**, *18*, 770–796. [\[CrossRef\]](#) [\[PubMed\]](#)
45. Bender, A.T.; Beavo, J.A. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. *Pharmacol. Rev.* **2006**, *58*, 488–520. [\[CrossRef\]](#)
46. Dubey, R.K.; Mi, Z.C.; Gillespie, D.G.; Jackson, E.K. Cyclic AMP Adenosine pathway inhibits vascular smooth muscle cell growth. *Hypertension* **1996**, *28*, 765–771. [\[CrossRef\]](#)

47. Begum, N.; Hockman, S.; Manganiello, V.C. Phosphodiesterase 3A (PDE3A) Deletion Suppresses Proliferation of Cultured Murine Vascular Smooth Muscle Cells (VSMCs) via Inhibition of Mitogen-activated Protein Kinase (MAPK) Signaling and Alterations in Critical Cell Cycle Regulatory Proteins. *J. Biol. Chem.* **2011**, *286*, 26238–26249. [[CrossRef](#)]
48. Yoo, A.R.; Koh, S.H.; Cho, G.W.; Kim, S.H. Inhibitory Effects of Cilostazol on Proliferation of Vascular Smooth Muscle Cells (VSMCs) Through Suppression of the ERK1/2 Pathway. *J. Atheroscler. Thromb.* **2010**, *17*, 1009–1018. [[CrossRef](#)]
49. Cai, Y.J.; Nagel, D.J.; Zhou, Q.; Cygnar, K.D.; Zhao, H.Q.; Li, F.Q.; Pi, X.C.; Knight, P.A.; Yan, C. Role of cAMP-Phosphodiesterase 1C Signaling in Regulating Growth Factor Receptor Stability, Vascular Smooth Muscle Cell Growth, Migration, and Neointimal Hyperplasia. *Circ. Res.* **2015**, *116*, 1120–1132. [[CrossRef](#)]
50. Nagel, D.J.; Aizawa, T.; Jeon, K.I.; Liu, W.M.; Mohan, A.; Wei, H.; Miano, J.M.; Florio, V.A.; Gao, P.J.; Korshunov, V.A.; et al. Role of nuclear Ca²⁺/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. *Circ. Res.* **2006**, *98*, 777–784. [[CrossRef](#)]
51. Zhang, L.; Bouadjel, K.; Manoury, B.; Vandecasteele, G.; Fischmeister, R.; Leblais, V. Cyclic nucleotide signalling compartmentation by PDEs in cultured vascular smooth muscle cells. *Br. J. Pharmacol.* **2019**, *176*, 1780–1792. [[CrossRef](#)]
52. Begum, N.; Shen, W.X.; Manganiello, V. Role of PDE3A in regulation of cell cycle progression in mouse vascular smooth muscle cells and oocytes: Implications in cardiovascular diseases and infertility. *Curr. Opin. Pharmacol.* **2011**, *11*, 725–729. [[CrossRef](#)]
53. Querolfferr, V.; Hultgardhnilsson, A.; Ringertz, N.R.; Nilsson, J.; Jonzon, B. Adenosine receptors, cyclic-AMP accumulation, and DNA-synthesis in aortic smooth-muscle cell-cultures of adult and neonatal rats. *J. Cell. Physiol.* **1992**, *151*, 555–560. [[CrossRef](#)] [[PubMed](#)]
54. Dubey, R.K.; Gillespie, D.G.; Mi, Z.C.; Rosselli, M.; Keller, P.J.; Jackson, E.K. Estradiol inhibits smooth muscle cell growth in part by activating the cAMP-adenosine pathway. *Hypertension* **2000**, *35*, 262–266. [[CrossRef](#)] [[PubMed](#)]
55. Dubey, R.K.; Gillespie, D.G.; Osaka, K.; Suzuki, F.; Jackson, E.K. Adenosine inhibits growth of rat aortic smooth muscle cells - Possible role of A(2b) receptor. *Hypertension* **1996**, *27*, 786–793. [[CrossRef](#)] [[PubMed](#)]
56. Dubey, R.K.; Gillespie, D.G.; Mi, Z.C.; Jackson, E.K. Adenosine inhibits growth of human aortic smooth muscle cells via A(2B) receptors. *Hypertension* **1998**, *31*, 516–521. [[CrossRef](#)] [[PubMed](#)]
57. Gordon, E.L.; Pearson, J.D.; Dickinson, E.S.; Moreau, D.; Slakey, L.L. The hydrolysis of extracellular adenine-nucleotides by arterial smooth-muscle cells - Regulation of adenosine production at the cell-surface. *J. Biol. Chem.* **1989**, *264*, 18986–18992. [[PubMed](#)]
58. Dubey, R.K.; Gillespie, D.G.; Shue, H.; Jackson, E.K. A(2B) receptors mediate antimitogenesis in vascular smooth muscle cells. *Hypertension* **2000**, *35*, 267–272. [[CrossRef](#)] [[PubMed](#)]
59. Bot, I.; de Vries, H.; Korporaal, S.J.A.; Foks, A.C.; Bot, M.; van Veldhoven, J.; ter Borg, M.N.D.; van Santbrink, P.J.; van Berkel, T.J.C.; Kuiper, J.; et al. Adenosine A(2B) Receptor Agonism Inhibits Neointimal Lesion Development After Arterial Injury in Apolipoprotein E-Deficient Mice. *Arterioscler. Thromb. Vasc. Biol.* **2012**, *32*, 2197–2205. [[CrossRef](#)]
60. Yang, D.; Koupenova, M.; McCrann, D.J.; Kopeikina, K.J.; Kagan, H.M.; Schreiber, B.M.; Ravid, K. The A2b adenosine receptor protects against vascular injury. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 792–796. [[CrossRef](#)]
61. Dubey, R.K.; Fingerle, J.; Gillespie, D.G.; Mi, Z.C.; Rosselli, M.; Imthurn, B.; Jackson, E.K. Adenosine Attenuates Human Coronary Artery Smooth Muscle Cell Proliferation by Inhibiting Multiple Signaling Pathways That Converge on Cyclin D. *Hypertension* **2015**, *66*, 1207–1219. [[CrossRef](#)]
62. Asada, Y.; Kisanuki, A.; Hatakeyama, K.; Takahama, S.; Koyama, T.; Kurozumi, S.; Sumiyoshi, A. Inhibitory effects of prostacyclin analog, TFC-132, on aortic neointimal thickening in-vivo and smooth-muscle cell proliferation in-vitro. *Prostaglandins Leukot. Essent. Fat. Acids* **1994**, *51*, 245–248. [[CrossRef](#)]
63. Shirotani, M.; Yui, Y.; Hattori, R.; Kawai, C. U-61, 431F, A stable prostacyclin analog, inhibits the proliferation of bovine vascular smooth-muscle cells with little antiproliferative effect on endothelial-cells. *Prostaglandins Other Lipid Mediat.* **1991**, *41*, 97–110. [[CrossRef](#)]
64. Falcetti, E.; Hall, S.M.; Phillips, P.G.; Patel, J.; Morrell, N.W.; Haworth, S.G.; Clapp, L.H. Smooth Muscle Proliferation and Role of the Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial Hypertension. *Am. J. Respir. Crit. Care Med.* **2010**, *182*, 1161–1170. [[CrossRef](#)] [[PubMed](#)]

65. Kandarpa, K.; Nakatsuka, S.; Yousuf, N.; Barry, J.J. Site-specific delivery of iloprost during experimental angioplasty suppresses smooth muscle cell proliferation. *J. Vasc. Interv. Radiol.* **1998**, *9*, 487–493. [\[CrossRef\]](#)
66. Alt, E.; Haehnel, I.; Beilharz, C.; Prietzel, K.; Preter, D.; Stemberger, A.; Fliedner, T.; Erhardt, W.; Schomig, A. Inhibition of neointima formation after experimental coronary artery stenting - A new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost. *Circulation* **2000**, *101*, 1453–1458. [\[CrossRef\]](#)
67. Clapp, L.H.; Finney, P.; Turcato, S.; Tran, S.; Rubin, L.J.; Tinker, A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. *Am. J. Respir. Cell Mol. Biol.* **2002**, *26*, 194–201. [\[CrossRef\]](#)
68. Hoshikawa, Y.; Voelkel, N.F.; Gesell, T.L.; Moore, M.D.; Morris, K.G.; Alger, L.A.; Narumiya, S.; Geraci, M.W. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. *Am. J. Respir. Crit. Care Med.* **2001**, *164*, 314–318. [\[CrossRef\]](#)
69. Al-Badawi, H.; Soler, H.M.; Watkins, M.T. Effects of prolonged hypoxia, reoxygenation, and shear stress on bovine aortic endothelial cell prostacyclin production. *Prostaglandins Other Lipid Mediat.* **1998**, *55*, 127–139. [\[CrossRef\]](#)
70. Jeremy, J.Y.; Izzat, M.B.; Birkett, S.D.; Knight, D.M.; Bryan, A.J.; Angelini, G.D. Reduced prostacyclin and increased leukotriene B-4 synthesis in porcine venous arterial grafts. *Ann. Thorac. Surg.* **1996**, *61*, 143–148. [\[CrossRef\]](#)
71. Roovers, K.; Assoian, R.K. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. *BioEssays* **2000**, *22*, 818–826. [\[CrossRef\]](#)
72. Burgering, B.; Bos, J. Regulation of Ras-mediated signaling - more than one-way to skin a cat. *Trends Biochem. Sci.* **1995**, *20*, 18–22. [\[CrossRef\]](#)
73. Burgering, B.M.T.; Pronk, G.J.; Vanweeren, P.C.; Chardin, P.; Bos, J.L. cAMP antagonizes p21(Ras)-directed activation of extracellular signal-regulated kinase-2 and phosphorylation of mSOS nucleotide exchange factor. *Embo J.* **1993**, *12*, 4211–4220. [\[CrossRef\]](#)
74. Graves, L.M.; Bornfeldt, K.E.; Raines, E.W.; Potts, B.C.; Macdonald, S.G.; Ross, R.; Krebs, E.G. Protein Kinase-A antagonizes platelet-derived growth factor-induced signalling by mitogen-activated protein-kinase in human arterial smooth-muscle cells. *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 10300–10304. [\[CrossRef\]](#)
75. Kahan, C.; Seuwen, K.; Meloche, S.; Pouyssegur, J. Coordinate, biphasic activation of p44 mitogen-activated protein-kinase and S6 kinase by growth-factors in hamster fibroblasts - evidence for thrombin-induced signals different from phosphoinositide turnover and adenylycyclase inhibition. *J. Biol. Chem.* **1992**, *267*, 13369–13375.
76. McKenzie, F.; Pouyssegur, J. cAMP-mediated growth inhibition in fibroblasts is not mediated via mitogen-activated protein (MAP) kinase (ERK) inhibition - cAMP-dependent protein kinase induces a temporal shift in growth factor-stimulated MAP kinases. *J. Biol. Chem.* **1996**, *271*, 13476–13483. [\[CrossRef\]](#)
77. Cospedal, R.; Lobo, M.; Zachary, I. Differential regulation of extracellular signal-regulated protein kinases (ERKs) 1 and 2 by cAMP and dissociation of ERK inhibition from anti-mitogenic effects in rabbit vascular smooth muscle cells. *Biochem. J.* **1999**, *342*, 407–414. [\[CrossRef\]](#)
78. Kronemann, N.; Nockher, W.; Busse, R.; Schini-Kerth, V. Growth-inhibitory effect of cyclic GMP- and cyclic AMP-dependent vasodilators on rat vascular smooth muscle cells: Effect on cell cycle and cyclin expression. *Br. J. Pharmacol.* **1999**, *126*, 349–357. [\[CrossRef\]](#)
79. Hewer, R.C.; Sala-Newby, G.B.; Wu, Y.J.; Newby, A.C.; Bond, M. PKA and Epac synergistically inhibit smooth muscle cell proliferation. *J. Mol. Cell. Cardiol.* **2011**, *50*, 87–98. [\[CrossRef\]](#)
80. Assender, J.; Southgate, K.; Hallett, M.; Newby, A. Inhibition of proliferation, but not of Ca²⁺ mobilization by cyclic AMP and GMP in rabbit aortic smooth-muscle cells. *Biochem. J.* **1992**, *288*, 527–532. [\[CrossRef\]](#)
81. Loesberg, C.; Vanwijk, R.; Zandbergen, J.; Vanaken, W.G.; Vanmourik, J.A.; Degroot, P.G. Cell cycle-dependent inhibition of human vascular smooth-muscle cell-proliferation by prostaglandin-E1. *Exp. Cell Res.* **1985**, *160*, 117–125. [\[CrossRef\]](#)
82. Dubravka, D.; Scott, D.W. Regulation of the G1 phase of the mammalian cell cycle. *Cell Res.* **2000**, *10*, 1–16. [\[CrossRef\]](#)
83. Vadiveloo, P.K.; Filonzi, E.L.; Stanton, H.R.; Hamilton, J.A. G1 phase arrest of human smooth muscle cells by heparin, IL-4 and cAMP is linked to repression of cyclin D1 and cdk2. *Atherosclerosis* **1997**, *133*, 61–69. [\[CrossRef\]](#)
84. Fukumoto, S.; Koyama, H.; Hosoi, M.; Yamakawa, K.; Tanaka, S.; Morii, H.; Nishizawa, Y. Distinct role of cAMP and cGMP in the cell cycle control of vascular smooth muscle cells - cGMP delays cell cycle transition

- through suppression of cyclin D1 and cyclin-dependent kinase 4 activation. *Circ. Res.* **1999**, *85*, 985–991. [[CrossRef](#)] [[PubMed](#)]
85. Musa, N.L.; Ramakrishnan, M.; Li, J.; Kartha, S.; Liu, P.; Pestell, R.G.; Hershenson, M.B. Forskolin inhibits cyclin D-1 expression in cultured airway smooth-muscle cells. *Am. J. Respir. Cell Mol. Biol.* **1999**, *20*, 352–358. [[CrossRef](#)] [[PubMed](#)]
 86. Bennett, M.R.; Littlewood, T.D.; Hancock, D.C.; Evan, G.I.; Newby, A.C. Down-regulation of the c-myc protooncogene in inhibition of vascular smooth-muscle cell-proliferation - a signal for growth arrest. *Biochem. J.* **1994**, *302*, 701–708. [[CrossRef](#)]
 87. Bouchard, C.; Thieke, K.; Maier, A.; Saffrich, R.; Hanley-Hyde, J.; Ansorge, W.; Reed, S.; Sicinski, P.; Bartek, J.; Eilers, M. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. *Embo J.* **1999**, *18*, 5321–5333. [[CrossRef](#)]
 88. Bennett, M.R.; Evan, G.I.; Newby, A.C. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth-muscle cells by serum reduction, interferon-gamma, heparin, and cyclic-nucleotide analogs and induces apoptosis. *Circ. Res.* **1994**, *74*, 525–536. [[CrossRef](#)]
 89. LAllemain, G.; Lavoie, J.; Rivard, N.; Baldin, V.; Pouyssegur, J. Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in fibroblasts. *Oncogene* **1997**, *14*, 1981–1990. [[CrossRef](#)]
 90. Kamiya, K.; Sakakibara, K.; Ryer, E.J.; Hom, R.P.; Leof, E.B.; Kent, K.C.; Liu, B. Phosphorylation of the cyclic AMP response element binding protein mediates transforming growth factor beta-induced downregulation of cyclin A in vascular smooth muscle cells. *Mol. Cell. Biol.* **2007**, *27*, 3489–3498. [[CrossRef](#)]
 91. Kothapalli, D.; Stewart, S.A.; Smyth, E.M.; Azonobi, I.; Pure, E.; Assoian, R.K. Prostacyclin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin A gene expression. *Mol. Pharmacol.* **2003**, *64*, 249–258. [[CrossRef](#)]
 92. Sherr, C.J.; Roberts, J.M. CDK inhibitors: Positive and negative regulators of G(1)-phase progression. *Genes Dev.* **1999**, *13*, 1501–1512. [[CrossRef](#)]
 93. Sherr, C.; Roberts, J. Inhibitors of mammalian G1 cyclin-dependent kinases. *Genes Dev.* **1995**, *9*, 1149–1163. [[CrossRef](#)] [[PubMed](#)]
 94. Bond, M.; Wu, Y.J.; Sala-Newby, G.B.; Newby, A.C. Rho GTPase, Rac(1), regulates Skp(2) levels, vascular smooth muscle cell proliferation, and intima formation in vitro and in vivo. *Cardiovasc. Res.* **2008**, *80*, 290–298. [[CrossRef](#)]
 95. Hayashi, S.; Morishita, R.; Matsushita, H.; Nakagami, H.; Taniyama, Y.; Nakamura, T.; Aoki, M.; Yamamoto, K.; Higaki, J.; Ogihara, T. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. *Hypertension* **2000**, 237–243. [[CrossRef](#)]
 96. Kadowaki, M.; Mizuno, S.; Demura, Y.; Ameshima, S.; Miyamori, I.; Ishizaki, T. Effect of hypoxia and Beraprost sodium on human pulmonary arterial smooth muscle cell proliferation: The role of p27kip1. *Respir. Res.* **2007**, *8*, 11. [[CrossRef](#)]
 97. Castagnino, P.; Kothapalli, D.; Hawthorne, E.A.; Xu, T.; Assoian, R.K. Cell-type- and cell-cycle-specific anti-mitogenesis by cicaprost. *Prostaglandins Other Lipid Mediat.* **2010**, *93*, 20–24. [[CrossRef](#)]
 98. Lu, Z.M.; Hunter, T. Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors. *Cell Cycle* **2010**, *9*, 2342–2352. [[CrossRef](#)]
 99. Pagano, M.; Tam, S.; Theodoras, A.; Beerromero, P.; Delsal, G.; Chau, V.; Yew, P.; Draetta, G.; Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. *Science* **1995**, *269*, 682–685. [[CrossRef](#)]
 100. Carrano, A.; Eytan, E.; Hershko, A.; Pagano, M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. *Nat. Cell Biol.* **1999**, *1*, 193–199. [[CrossRef](#)]
 101. Bond, M.; Sala-Newby, G.B.; Wu, Y.J.; Newby, A.C. Biphasic effect of p21(Cip1) on vascular smooth muscle cell proliferation: Role of phosphatidylinositol 3-kinase signalling and Skp2-mediated degradation. *Circulation* **2005**, *112*, U172–U173.
 102. Izzard, T.; Taylor, C.; Birkett, S.; Jackson, C.; Newby, A. Mechanisms underlying maintenance of smooth muscle cell quiescence in rat aorta: Role of the cyclin dependent kinases and their inhibitors. *Cardiovasc Res* **2002**, *52*, 242–252. [[CrossRef](#)]
 103. Hernandez-Negrete, I.; Sala-Newby, G.B.; Perl, A.; Kunkel, G.R.; Newby, A.C.; Bond, M. Adhesion-dependent Skp2 transcription requires selenocysteine tRNA gene transcription-activating factor (STAF). *Biochem. J.* **2011**, *436*, 133–143. [[CrossRef](#)] [[PubMed](#)]

104. Walsh, D.A.; Perkins, J.P.; Krebs, E.G. An adenosine 3', 5'-monophosphate-dependant protein kinase from rabbit skeletal muscle. *J. Biol. Chem.* **1968**, *243*, 3763.
105. Sjöberg, T.J.; Kornev, A.P.; Taylor, S.S. Dissecting the cAMP-inducible allosteric switch in protein kinase A RI alpha. *Protein Sci.* **2010**, *19*, 1213–1221. [[CrossRef](#)]
106. Yang, S.M.; Fletcher, W.H.; Johnson, D.A. Regulation of cAMP-dependent protein-kinase - enzyme activation without dissociation. *Biochemistry* **1995**, *34*, 6267–6271. [[CrossRef](#)] [[PubMed](#)]
107. Smith, F.D.; Esseltine, J.L.; Nygren, P.J.; Veessler, D.; Byrne, D.P.; Vonderach, M.; Strashnov, I.; Eysers, C.E.; Eysers, P.A.; Langeberg, L.K.; et al. Local protein kinase A action proceeds through intact holoenzymes. *Science* **2017**, *356*, 1288–1293. [[CrossRef](#)]
108. Smith, F.D.; Reichow, S.L.; Esseltine, J.L.; Shi, D.; Langeberg, L.K.; Scott, J.D.; Gonen, T. Intrinsic disorder within an AKAP-protein kinase A complex guides local substrate phosphorylation. *Elife* **2013**, *2*. [[CrossRef](#)]
109. Walker-Gray, R.; Stengel, F.; Gold, M.G. Mechanisms for restraining cAMP-dependent protein kinase revealed by subunit quantitation and cross-linking approaches. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 10414–10419. [[CrossRef](#)]
110. Dostmann, W.R.G.; Taylor, S.S.; Genieser, H.G.; Jastorff, B.; Doskeland, S.O.; OGREID, D. Probing the cyclic-nucleotide binding-sites of cAMP-dependent protein kinase-I and kinase-II with analogs of adenosine 3', 5'-cyclic phosphorothioates. *J. Biol. Chem.* **1990**, *265*, 10484–10491.
111. Cummings, D.E.; Brandon, E.P.; Planas, J.V.; Motamed, K.; Idzerda, R.L.; McKnight, G.S. Genetically lean mice result from targeted disruption of the RII beta subunit of protein kinase A. *Nature* **1996**, *382*, 622–626. [[CrossRef](#)]
112. Corbin, J.D.; Keely, S.L.; Park, C.R. Distribution and dissociation of cyclic adenosine 3', 5'-monophosphate-dependent protein kinases in adipose, cardiac, and other tissues. *J. Biol. Chem.* **1975**, *250*, 218–225.
113. Hofmann, F.; Bechtel, P.J.; Krebs, E.G. Concentrations of cyclic AMP-dependent protein-kinase subunits in various tissues. *J. Biol. Chem.* **1977**, *252*, 1441–1447.
114. Joachim, S.; Schwach, G. Localization of camp-dependent protein-kinase subunits along the secretory pathway in pancreatic and parotid acinar-cells and accumulation of the catalytic subunit in parotid secretory granules following beta-adrenergic stimulation. *Eur. J. Cell Biol.* **1990**, *51*, 76–84.
115. Osinski, M.T.; Schror, K. Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors - Role of protein kinase A in vascular smooth muscle cell mitogenesis. *Biochem. Pharmacol.* **2000**, *60*, 381–387. [[CrossRef](#)]
116. Yan, H.D.; Deshpande, D.A.; Misior, A.M.; Miles, M.C.; Saxena, H.; Riemer, E.C.; Pascual, R.M.; Panettieri, R.A.; Penn, R.B. Anti-mitogenic effects of beta-agonists and PGE(2) on airway smooth muscle are PKA dependent. *Faseb J.* **2011**, *25*, 389–397. [[CrossRef](#)]
117. Schmitt, J.; Stork, P. PKA phosphorylation of Src mediated cAMP's inhibition of cell growth via Rap1. *Mol. Cell* **2002**, *9*, 85–94. [[CrossRef](#)]
118. Indolfi, C.; Stabile, E.; Coppola, C.; Gallo, A.; Perrino, C.; Allevato, G.; Cavuto, L.; Torella, D.; Di Lorenzo, E.; Troncone, G.; et al. Membrane-bound protein kinase a inhibits smooth muscle cell proliferation in vitro and in vivo by amplifying cAMP-protein kinase a signals. *Circ. Res.* **2001**, *88*, 319–324. [[CrossRef](#)]
119. Torella, D.; Gasparri, C.; Ellison, G.M.; Curcio, A.; Leone, A.; Vicinanza, C.; Galuppo, V.; Mendicino, I.; Sacco, W.; Aquila, I.; et al. Differential regulation of vascular smooth muscle and endothelial cell proliferation in vitro and in vivo by cAMP/PKA-activated p85 alpha(PI3K). *Am. J. Physiol. -Heart Circ. Physiol.* **2009**, *297*, H2015–H2025. [[CrossRef](#)]
120. Taurin, S.; Sandbo, N.; Yau, D.M.; Sethakorn, N.; Dulin, N.O. Phosphorylation of beta-catenin by PKA promotes ATP-induced proliferation of vascular smooth muscle cells. *Am. J. Physiol.-Cell Physiol.* **2008**, *294*, C1169–C1174. [[CrossRef](#)]
121. Kassel, K.M.; Wyatt, T.A.; Panettieri, R.A.; Toews, M.L. Inhibition of human airway smooth muscle cell proliferation by beta(2)-adrenergic receptors and cAMP is PKA independent: Evidence for EPAC involvement. *Am. J. Physiol. -Lung Cell. Mol. Physiol.* **2008**, *294*, L131–L138.
122. Shabb, J.B. Physiological substrates of cAMP-dependent protein kinase. *Chem. Rev.* **2001**, *101*, 2381–2411. [[CrossRef](#)]
123. Chen, L.H.; Daum, G.; Chitaley, K.; Coats, S.A.; Bowen-Pope, D.F.; Eigenthaler, M.; Thumati, N.R.; Walter, U.; Clowes, A.W. Vasodilator-stimulated phosphoprotein regulates proliferation and growth inhibition by nitric oxide in vascular smooth muscle cells. *Arterioscler. Thromb. Vasc. Biol.* **2004**, *24*, 1403–1408. [[CrossRef](#)]

124. Davis, A.; Hogarth, K.; Fernandes, D.; Solway, J.; Niu, J.X.; Kolenko, V.; Browning, D.; Miano, J.M.; Orlov, S.N.; Dulin, N.O. Functional significance of protein kinase A activation by endothelin-1 and ATP: Negative regulation of SRF-dependent gene expression by PKA. *Cell. Signal.* **2003**, *15*, 597–604. [[CrossRef](#)]
125. White, R.E.; Kryman, J.P.; El-Mowafy, A.M.; Han, G.C.; Carrier, G.O. cAMP-dependent vasodilators cross-activate the cGMP-dependent protein kinase to stimulate BKCa channel activity in coronary artery smooth muscle cells. *Circ. Res.* **2000**, *86*, 897–905. [[CrossRef](#)]
126. Lincoln, T.M.; Cornwell, T.L.; Taylor, A.E. cGMP-dependent protein-kinase mediates the reduction of Ca^{2+} by camp in vascular smooth-muscle cells. *Am. J. Physiol.* **1990**, *258*, C399–C407. [[CrossRef](#)] [[PubMed](#)]
127. VanSchouwen, B.; Selvaratnam, R.; Giri, R.; Lorenz, R.; Herberg, F.W.; Kim, C.; Melacini, G. Mechanism of cAMP Partial Agonism in Protein Kinase G (PKG). *J. Biol. Chem.* **2015**, *290*, 28631–28641. [[CrossRef](#)] [[PubMed](#)]
128. de Rooij, J.; Zwartkruis, F.J.T.; Verheijen, M.H.G.; Cool, R.H.; Nijman, S.M.B.; Wittinghofer, A.; Bos, J.L. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. *Nature* **1998**, *396*, 474–477. [[CrossRef](#)] [[PubMed](#)]
129. Kawasaki, H.; Springett, G.M.; Mochizuki, N.; Toki, S.; Nakaya, M.; Matsuda, M.; Housman, D.E.; Graybiel, A.M. A family of cAMP-binding proteins that directly activate Rap1. *Science* **1998**, *282*, 2275–2279. [[CrossRef](#)] [[PubMed](#)]
130. de Rooij, J.; Rehmann, H.; van Triest, M.; Cool, R.H.; Wittinghofer, A.; Bos, J.L. Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs. *J. Biol. Chem.* **2000**, *275*, 20829–20836. [[CrossRef](#)]
131. Bacallao, K.; Monje, P.V. Opposing Roles of pka and epac in the cAMP-Dependent Regulation of Schwann Cell Proliferation and Differentiation. *PLoS ONE* **2013**, *8*. [[CrossRef](#)]
132. Broecker-Preuss, M.; Baten, J.; Sheu-Grabellus, S.Y.; Gorges, R.; Bockisch, A.; Schmid, K.W.; Fuhrer, D.; Mann, K. Expression of the cAMP Binding Protein EPAC1 in Thyroid Tumors and Growth Regulation of Thyroid Cells and Thyroid Carcinoma Cells by EPAC Proteins. *Horm. Metab. Res.* **2015**, *47*, 200–208. [[CrossRef](#)]
133. Gao, M.; Ma, Y.Y.; Bast, R.C.; Li, Y.; Wan, L.; Liu, Y.P.; Sun, Y.S.; Fang, Z.H.; Zhang, L.N.; Wang, X.Y.; et al. Epac1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/Cyclin D1/CDK4 pathway in vitro and in vivo. *Med Oncol.* **2016**, *33*. [[CrossRef](#)]
134. Grandoch, M.; Rose, A.; ter Braak, M.; Jendrossek, V.; Rubben, H.; Fischer, J.W.; Schmidt, M.; Weber, A.A. Epac inhibits migration and proliferation of human prostate carcinoma cells. *Br. J. Cancer* **2009**, *101*, 2038–2042. [[CrossRef](#)]
135. Haag, S.; Warnken, M.; Juergens, U.; Racke, K. Role of Epac1 in mediating anti-proliferative effects of prostanoid EP2 receptors and cAMP in human lung fibroblasts. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **2008**, *378*, 617–630. [[CrossRef](#)]
136. Hochbaum, D.; Hong, K.; Barila, G.; Ribeiro-Neto, F.; Altschuler, D.L. Epac, in synergy with cAMP-dependent protein kinase (PKA), is required for cAMP-mediated mitogenesis. *J. Biol. Chem.* **2008**, *283*, 4464–4468. [[CrossRef](#)]
137. Kelly, P.; Bailey, C.L.; Fueger, P.T.; Newgard, C.B.; Casey, P.J.; Kimple, M.E. Rap1 Promotes Multiple Pancreatic Islet Cell Functions and Signals through Mammalian Target of Rapamycin Complex 1 to Enhance Proliferation. *J. Biol. Chem.* **2010**, *285*, 15777–15785. [[CrossRef](#)] [[PubMed](#)]
138. Kiermayer, S.; Biondi, R.M.; Imig, J.; Plotz, G.; Haupenthal, J.; Zeuzem, S.; Piiper, A. Epac activation converts cAMP from a proliferative into a differentiation signal in PC12 Cells. *Mol. Biol. Cell* **2005**, *16*, 5639–5648. [[CrossRef](#)]
139. Kimura, T.E.; Duggirala, A.; Hindmarch, C.C.T.; Hewer, R.C.; Cui, M.Z.; Newby, A.C.; Bond, M. Inhibition of Egr1 expression underlies the anti-mitogenic effects of cAMP in vascular smooth muscle cells. *J. Mol. Cell. Cardiol.* **2014**, *72*, 9–19. [[CrossRef](#)]
140. Mayer, P.; Hinze, A.V.; Harst, A.; von Kugelgen, I. A(2B) receptors mediate the induction of early genes and inhibition of arterial smooth muscle cell proliferation via Epac. *Cardiovasc. Res.* **2011**, *90*, 148–156. [[CrossRef](#)]
141. Misra, U.K.; Pizzo, S.V. Epac1-Induced Cellular Proliferation in Prostate Cancer Cells Is Mediated by B-Raf/ERK and mTOR Signaling Cascades. *J. Cell. Biochem.* **2009**, *108*, 998–1011. [[CrossRef](#)] [[PubMed](#)]
142. Roscioni, S.S.; Dekkers, B.G.J.; Prins, A.G.; Menzen, M.H.; Meurs, H.; Schmidt, M.; Maarsingh, H. cAMP inhibits modulation of airway smooth muscle phenotype via the exchange protein activated by cAMP (Epac) and protein kinase A. *Br. J. Pharmacol.* **2011**, *162*, 193–209. [[CrossRef](#)]

143. Sun, W.; Jiao, W.; Huang, Y.M.; Li, R.; Zhang, Z.; Wang, J.W.; Lei, T. Exchange proteins directly activated by cAMP induce the proliferation of rat anterior pituitary GH3 cells via the activation of extracellular signal-regulated kinase. *Biochem. Biophys. Res. Commun.* **2017**, *485*, 355–359. [[CrossRef](#)]
144. Vitali, E.; Cambiaghi, V.; Spada, A.; Tresoldi, A.; Zerbi, A.; Peverelli, E.; Carnaghi, C.; Mantovani, G.; Lania, A.G. cAMP effects in neuroendocrine tumors: The role of Epac and PKA in cell proliferation and adhesion. *Exp. Cell Res.* **2015**, *339*, 241–251. [[CrossRef](#)]
145. Vitali, E.; Peverelli, E.; Giardino, E.; Locatelli, M.; Lasio, G.B.; Beck-Peccoz, P.; Spada, A.; Lania, A.G.; Mantovani, G. Cyclic adenosine 3'-5'-monophosphate (cAMP) exerts proliferative and anti-proliferative effects in pituitary cells of different types by activating both cAMP-dependent protein kinase A (PKA) and exchange proteins directly activated by cAMP (Epac). *Mol. Cell. Endocrinol.* **2014**, *383*, 193–202. [[CrossRef](#)]
146. Wang, X.S.; Luo, C.; Cheng, X.D.; Lu, M.L. Lithium and an EPAC-specific inhibitor ESI-09 synergistically suppress pancreatic cancer cell proliferation and survival. *Acta Biochim. Et Biophys. Sin.* **2017**, *49*, 573–580. [[CrossRef](#)]
147. Yang, Y.; Yang, F.; Wu, X.J.; Lv, X.W.; Li, J. EPAC activation inhibits acetaldehyde-induced activation and proliferation of hepatic stellate cell via Rap1. *Can. J. Physiol. Pharmacol.* **2016**, *94*, 498–507. [[CrossRef](#)]
148. McKean, J.S.; Murray, F.; Gibson, G.; Shewan, D.A.; Tucker, S.J.; Nixon, G.F. The cAMP-producing agonist beraprost inhibits human vascular smooth muscle cell migration via exchange protein directly activated by cAMP. *Cardiovasc. Res.* **2015**, *107*, 546–555. [[CrossRef](#)]
149. Phosri, S.; Arieyawong, A.; Bunrukchai, K.; Parichatikanond, W.; Nishimura, A.; Nishida, M.; Mangmool, S. Stimulation of Adenosine A(2B) Receptor Inhibits Endothelin-1-Induced Cardiac Fibroblast Proliferation and alpha-Smooth Muscle Actin Synthesis Through the cAMP/Epac/PI3K/Akt-Signaling Pathway. *Front. Pharmacol.* **2017**, *8*, 15. [[CrossRef](#)] [[PubMed](#)]
150. Roscioni, S.S.; Prins, A.G.; Elzinga, C.R.S.; Menzen, M.H.; Dekkers, B.G.J.; Halayko, A.J.; Meurs, H.; Maarsingh, H.; Schmidt, M. Protein kinase A and the exchange protein directly activated by cAMP (Epac) modulate phenotype plasticity in human airway smooth muscle. *Br. J. Pharmacol.* **2011**, *164*, 958–969. [[CrossRef](#)]
151. Jang, M.W.; Yun, S.P.; Park, J.H.; Ryu, J.M.; Lee, J.H.; Han, H.J. Cooperation of Epac1/Rap1/Akt and PKA in prostaglandin E2-induced proliferation of human umbilical cord blood derived mesenchymal stem cells: Involvement of c-Myc and VEGF expression. *J. Cell. Physiol.* **2012**, *227*, 3756–3767. [[CrossRef](#)]
152. Yokoyama, U.; Minamisawa, S.; Quan, H.; Akaike, T.; Jin, M.H.; Otsu, K.; Ulucan, C.; Wang, X.; Baljinnyam, E.; Takaoka, M.; et al. Epac1 is upregulated during neointima formation and promotes vascular smooth muscle cell migration. *Am. J. Physiol. -Heart Circ. Physiol.* **2008**, *295*, H1547–H1555. [[CrossRef](#)]
153. Yokoyama, U.; Minamisawa, S.; Quan, H.; Akaike, T.; Suzuki, S.; Jin, M.; Jiao, Q.; Watanabe, M.; Otsu, K.; Iwasaki, S.; et al. Prostaglandin E-2-activated Epac promotes neointimal formation of the rat ductus arteriosus by a process distinct from that of cAMP-dependent protein kinase A. *J. Biol. Chem.* **2008**, *283*, 28702–28709. [[CrossRef](#)]
154. Kato, Y.; Yokoyama, U.; Yanai, C.; Ishige, R.; Kurotaki, D.; Umemura, M.; Fujita, T.; Kubota, T.; Okumura, S.; Sata, M.; et al. Epac1 Deficiency Attenuated Vascular Smooth Muscle Cell Migration and Neointimal Formation. *Arterioscler. Thromb. Vasc. Biol.* **2015**, *35*, 2617–2625. [[CrossRef](#)]
155. Wang, H.; Robichaux, W.G.; Wang, Z.Q.; Mei, F.C.; Cai, M.; Du, G.W.; Chen, J.; Cheng, X.D. Inhibition of Epac1 suppresses mitochondrial fission and reduces neointima formation induced by vascular injury. *Sci. Rep.* **2016**, *6*. [[CrossRef](#)]
156. Kitayama, H.; Sugimoto, Y.; Matsuzaki, T.; Ikawa, Y.; Noda, M. A Ras-related gene with transformation suppressor activity. *Cell* **1989**, *56*, 77–84. [[CrossRef](#)]
157. Frech, M.; John, J.; Pizon, V.; Chardin, P.; Tavittian, A.; Clark, R.; McCormick, F.; Wittinghofer, A. Inhibition of GTPase activating protein stimulation of Ras-p21 GTPase by the Krev-1 gene-product. *Science* **1990**, *249*, 169–171. [[CrossRef](#)]
158. Hata, Y.; Kikuchi, A.; Sasaki, T.; Schaber, M.D.; Gibbs, J.B.; Takai, Y. Inhibition of the Ras-p21 gtpase-activating protein-stimulated GTPase activity of C-HA-Ras-p21 by SMG-p21 having the same putative effector domain as Ras-p21s. *J. Biol. Chem.* **1990**, *265*, 7104–7107. [[PubMed](#)]
159. Ikeda, M.; Koyama, S.; Okazaki, M.; Dohi, K.; Kikuchi, A. Rap1 p21 regulates the interaction of Ras p21 with Rgl, a new effector protein of Ras p21. *Febs Lett.* **1995**, *375*, 37–40. [[CrossRef](#)]

160. Spaargaren, M.; Bischoff, J.R. Identification of the guanine-nucleotide dissociation stimulator for ral as a putative effector molecule of R-Ras, H-Ras, K-Ras, and Rap. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 6650. [\[CrossRef\]](#)
161. Urano, T.; Emkey, R.; Feig, L.A. Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation. *Embo J.* **1996**, *15*, 810–816. [\[CrossRef\]](#)
162. Zwartkruis, F.J.T.; Wolthuis, R.M.F.; Nabben, N.; Franke, B.; Bos, J.L. Extracellular signal-regulated activation of Rap1 fails to interfere in Ras effector signalling. *Embo J.* **1998**, *17*, 5905–5912. [\[CrossRef\]](#)
163. Ribeiro-Neto, F.; Urbani, J.; Lemee, N.; Lou, L.G.; Altschuler, D.L. On the mitogenic properties of Rap1b: cAMP-induced G(1)/S entry requires activated and phosphorylated Rap1b. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 5418–5423. [\[CrossRef\]](#) [\[PubMed\]](#)
164. Cook, S.J.; Rubinfeld, B.; Albert, I.; McCormick, F. RapV12 antagonizes Ras-dependent activation of Erk1 and Erk2 by LPA and RGF in rat-1 fibroblasts. *Embo J.* **1993**, *12*, 3475–3485. [\[CrossRef\]](#)
165. Li, Q.; Teng, Y.F.; Wang, J.; Yu, M.; Li, Y.Q.; Zheng, H. Rap1 promotes proliferation and migration of vascular smooth muscle cell via the ERK pathway. *Pathol. Res. Pract.* **2018**, *214*, 1045–1050. [\[CrossRef\]](#)
166. Kaupp, U.B.; Seifert, R. Cyclic nucleotide-gated ion channels. *Physiol. Rev.* **2002**, *82*, 769–824. [\[CrossRef\]](#)
167. Yao, X.Q.; Leung, P.S.; Kwan, H.Y.; Wong, T.P.; Fong, M.W. Rod-type cyclic nucleotide-gated cation channel is expressed in vascular endothelium and vascular smooth muscle cells. *Cardiovasc. Res.* **1999**, *41*, 282–290. [\[CrossRef\]](#)
168. Cheng, K.T.; Chan, F.L.; Huang, Y.; Chan, W.Y.; Yao, X.Q. Expression of olfactory-type cyclic nucleotide-gated channel (CNGA2) in vascular tissues. *Histochem. Cell Biol.* **2003**, *120*, 475–481. [\[CrossRef\]](#)
169. Froese, A.; Breher, S.S.; Waldeyer, C.; Schindler, R.F.R.; Nikolaev, V.O.; Rinne, S.; Wischmeyer, E.; Schlueter, J.; Becher, J.; Simrick, S.; et al. Popeye domain containing proteins are essential for stress-mediated modulation of cardiac pacemaking in mice. *J. Clin. Investig.* **2012**, *122*, 1119–1130. [\[CrossRef\]](#)
170. Smith, T.K.; Hager, H.A.; Francis, R.; Kilkenny, D.M.; Lo, C.W.; Bader, D.M. Bves directly interacts with GEFT, and controls cell shape and movement through regulation of Rac1/Cdc42 activity. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 8298–8303. [\[CrossRef\]](#)
171. Guo, X.G.; Stafford, L.J.; Bryan, B.; Xia, C.Z.; Ma, W.B.; Wu, X.S.; Liu, D.; Zhou, S.Y.; Liu, M.Y. A Rac/Cdc42-specific exchange factor, GEFT, induces cell proliferation, transformation, and migration. *J. Biol. Chem.* **2003**, *278*, 13207–13215. [\[CrossRef\]](#) [\[PubMed\]](#)
172. Hulin-Curtis, S.; Williams, H.; Wadey, K.S.; Sala-Newby, G.B.; George, S.J. Targeting Wnt/beta-Catenin Activated Cells with Dominant-Negative N-cadherin to Reduce Neointima Formation. *Mol. Ther. -Methods Clin. Dev.* **2017**, *5*, 191–199. [\[CrossRef\]](#)
173. Tsaousi, A.; Mill, C.; George, S.J. The Wnt pathways in vascular disease: Lessons from vascular development. *Curr. Opin. Lipidol.* **2011**, *22*, 350–357. [\[CrossRef\]](#)
174. Tsaousi, A.; Williams, H.; Lyon, C.A.; Taylor, V.; Swain, A.; Johnson, J.L.; George, S.J. Wnt4/beta-Catenin Signaling Induces VSMC Proliferation and Is Associated With Intimal Thickening. *Circ. Res.* **2011**, *108*, 427–436. [\[CrossRef\]](#)
175. Williams, H.; Mill, C.A.E.; Monk, B.A.; Hulin-Curtis, S.; Johnson, J.L.; George, S.J. Wnt2 and WISP-1/CCN4 Induce Intimal Thickening via Promotion of Smooth Muscle Cell Migration. *Arterioscler. Thromb. Vasc. Biol.* **2016**, *36*, 1417–1424. [\[CrossRef\]](#)
176. Parang, B.; Kaz, A.M.; Barrett, C.W.; Short, S.P.; Ning, W.; Keating, C.E.; Mittal, M.K.; Naik, R.D.; Washington, M.K.; Revetta, F.L.; et al. BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumorigenesis. *Gut* **2017**, *66*, 852–862. [\[CrossRef\]](#)
177. Pelletier, S.; Julien, C.; Popoff, M.; Lamarche-Vane, N.; Meloche, S. Cyclic AMP induces morphological changes of vascular smooth muscle cells by inhibiting a Rac-dependent signaling pathway. *J. Cell. Physiol.* **2005**, *204*, 412–422. [\[CrossRef\]](#)
178. Blirando, K.; Blaise, R.; Gorodnaya, N.; Rouxel, C.; Meilhac, O.; Vincent, P.; Limon, I. The stellate vascular smooth muscle cell phenotype is induced by IL-1 beta via the secretion of PGE(2) and subsequent cAMP-dependent protein kinase A activation. *Biochim. Et Biophys. Acta-Mol. Cell Res.* **2015**, *1853*, 3235–3247. [\[CrossRef\]](#)
179. Chaldakov, G.N.; Nabika, T.; Nara, Y.; Yamori, Y. Cyclic AMP and cytochalasin b-induced arborization in cultured aortic smooth-muscle cells - its cytopharmacological characterization. *Cell Tissue Res.* **1989**, *255*, 435–442. [\[CrossRef\]](#)

180. Gros, R.; Ding, Q.; Chorazyczewski, J.; Pickering, J.G.; Limbird, L.E.; Feldman, R.D. Adenylyl cyclase isoform-selective regulation of vascular smooth muscle proliferation and cytoskeletal reorganization. *Circ. Res.* **2006**, *99*, 845–852. [[CrossRef](#)]
181. Nabika, T.; Velletri, P.A.; Igawa, T.; Yamori, Y.; Lovenberg, W. Comparison of cyclic-AMP accumulation and morphological-changes induced by beta-adrenergic stimulation of cultured vascular smooth-muscle cells and fibroblasts. *Blood Vessel.* **1985**, *22*, 47–56.
182. Lang, P.; Gesbert, F.; DelespineCarmagnat, M.; Stancou, R.; Pouchelet, M.; Bertoglio, J. Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. *Embo J.* **1996**, *15*, 510–519. [[CrossRef](#)]
183. Ohta, Y.; Akiyama, T.; Nishida, E.; Sakai, H. Protein kinase C and cAMP-dependent protein kinase induce opposite effects on actin polymerizability. *FEBS Lett.* **1987**, *222*, 305–310. [[CrossRef](#)]
184. Glading, A.; Han, J.; Stockton, R.A.; Ginsberg, M.H. KRIT-1/CCM1 is a Rap1 effector that regulates endothelial cell-cell junctions. *J. Cell Biol.* **2007**, *179*, 247–254. [[CrossRef](#)] [[PubMed](#)]
185. Post, A.; Pannekoek, W.J.; Ponsioen, B.; Vliem, M.J.; Bos, J.L. Rap1 Spatially Controls ArhGAP29 To Inhibit Rho Signaling during Endothelial Barrier Regulation. *Mol. Cell. Biol.* **2015**, *35*, 2495–2502. [[CrossRef](#)]
186. Huang, S.; Chen, C.; Ingber, D. Control of Cyclin D1, p27kip1, and cell cycle progression in humna capillary endothelial cells by cell shape and cytoskeleton tension. *Mol. Biol. Cell* **1998**, *9*, 3179–3193. [[CrossRef](#)]
187. Huang, S.; Ingber, D. A discrete cell cycle checkpoint in late G1 that is cytoskeleton-dependent and MAP Kinase (ERK)-independent. *Exp. Cell Res.* **2002**, *275*, 255–264. [[CrossRef](#)]
188. Aplin, A.E.; Howe, A.K.; Juliano, R.L. Cell adhesion molecules, signal transduction and cell growth. *Curr. Opin. Cell Biol.* **1999**, *11*, 737–744. [[CrossRef](#)]
189. Schwartz, M.; Assoian, R. Integrins and cell proliferation: Regulation of cyclin-dependent kinases via cytoplasmic signalling pathways. *J. Cell. Sci.* **2001**, *114*, 2553–2560.
190. Duggirala, A.; Kimura, T.E.; Sala-Newby, G.B.; Johnson, J.L.; Wu, Y.-J.; Newby, A.C.; Bond, M. cAMP-induced actin cytoskeleton remodelling inhibits MKL1-dependent expression of the chemotactic and pro-proliferative factor, Ccn1. *J. Mol. Cell. Cardiol.* **2015**, *79*, 157–168. [[CrossRef](#)] [[PubMed](#)]
191. Kimura, T.E.; Duggirala, A.; Smith, M.C.; White, S.; Sala-Newby, G.B.; Newby, A.C.; Bond, M. The Hippo pathway mediates inhibition of vascular smooth muscle cell proliferation by cAMP. *J. Mol. Cell. Cardiol.* **2016**, *90*, 1–10. [[CrossRef](#)] [[PubMed](#)]
192. Ebrahimighaei, R.; McNeill, M.; Smith, S.; Wray, J.; Ford, K.; Newby, A.; Bond, M. Elevated cyclic-AMP represses expression of Exchange Protein Activated by cAMP (EPAC1) by inhibiting YAP-TEAD activity and HDAC-mediated histone deacetylation. *Bba - Mol. Cell Res.* **2019**, *1866*, 1634–1649.
193. Jackson, E.K.; Gillespie, D.G. Extracellular 2',3'-cAMP and 3',5' -cAMP stimulate proliferation of preglomerular vascular endothelial cells and renal epithelial cells. *Am. J. Physiol. -Ren. Physiol.* **2012**, *303*, F954–F962. [[CrossRef](#)]
194. Fantidis, P.; Fernandez-Ortiz, A.; Aragoncillo, P.; de Prada, T.P.; Sanmartin, M.; Lopez, J.; Sabate, M.; Escaned, J.; Alfonso, F.; Hernandez, R.; et al. Effect of cAMP on endothelial cell function and fibromuscular proliferation in an injured swine carotid and coronary artery. *Rev. Esp. De Cardiol.* **2001**, *54*, 981–989. [[CrossRef](#)]
195. Hill, C.S.; Wynne, J.; Treisman, R. The Rho-Family of GTPases RhoA, Rac1, and Cdc42 regulate transcriptional activation by SRF. *Cell* **1995**, *81*, 1159–1170. [[CrossRef](#)]
196. Graham, R.; Gilman, M. Distinct protein targets for signals acting at the c-fos serum response element. *Science* **1991**, *251*, 189–192. [[CrossRef](#)] [[PubMed](#)]
197. Posern, G.; Miralles, F.; Guettler, S.; Treisman, R. Mutant actins that stabilise F-actin use distinct mechanisms to activate the SRF coactivator MAL. *Embo J.* **2004**, *23*, 3973–3983. [[CrossRef](#)] [[PubMed](#)]
198. Copeland, J.W.; Treisman, R. The diaphanous-related formin mDia1 controls serum response factor activity through its effects on actin polymerization. *Mol. Biol. Cell* **2002**, *13*, 4088–4099. [[CrossRef](#)] [[PubMed](#)]
199. Geneste, O.; Copeland, J.W.; Treisman, R. LIM kinase and Diaphanous cooperate to regulate serum response factor and actin dynamics. *J. Cell Biol.* **2002**, *157*, 831–838. [[CrossRef](#)] [[PubMed](#)]
200. Grosse, R.; Copeland, J.W.; Newsome, T.P.; Way, M.; Treisman, R. A role for VASP in RhoA-diaphanous signalling to actin dynamics and SRF activity. *Embo J.* **2003**, *22*, 3050–3061. [[CrossRef](#)]
201. Miralles, F.; Posern, G.; Zaromytidou, A.I.; Treisman, R. Actin dynamics control SRF activity by regulation of its coactivator MAL. *Cell* **2003**, *113*, 329–342. [[CrossRef](#)]

202. Minami, T.; Kuwahara, K.; Nakagawa, Y.; Takaoka, M.; Kinoshita, H.; Nakao, K.; Kuwabara, Y.; Yamada, Y.; Yamada, C.; Shibata, J.; et al. Reciprocal expression of MRTF-A and myocardin is crucial for pathological vascular remodelling in mice. *Embo J.* **2012**, *31*, 4428–4440. [[CrossRef](#)]
203. Low, B.C.; Pan, C.Q.; Shivashankar, G.V.; Bershadsky, A.; Sudol, M.; Sheetz, M. YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth. *FEBS Lett.* **2014**, *588*, 2663–2670. [[CrossRef](#)] [[PubMed](#)]
204. Komuro, A.; Nagai, M.; Navin, N.E.; Sudol, M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. *J. Biol. Chem.* **2003**, *278*, 33334–33341. [[CrossRef](#)] [[PubMed](#)]
205. Hudson, C.; Kimura, T.E.; Duggirala, A.; Sala-Newby, G.B.; Newby, A.C.; Bond, M. Dual Role of CREB in The Regulation of VSMC Proliferation: Mode of Activation Determines Pro- or Anti-Mitogenic Function. *Sci. Rep.* **2018**, *8*, 15. [[CrossRef](#)] [[PubMed](#)]
206. Li, Z.; Zhao, B.; Wang, P.; Chen, F.; Dong, Z.H.; Yang, H.R.; Guan, K.L.; Xu, Y.H. Structural insights into the YAP and TEAD complex. *Genes Dev.* **2010**, *24*, 235–240. [[CrossRef](#)] [[PubMed](#)]
207. Dong, J.X.; Feldmann, G.; Huang, J.B.; Wu, S.; Zhang, N.L.; Comerford, S.A.; Gayyed, M.F.; Anders, R.A.; Maitra, A.; Pan, D.J. Elucidation of a universal size-control mechanism in Drosophila and mammals. *Cell* **2007**, *130*, 1120–1133. [[CrossRef](#)] [[PubMed](#)]
208. Hao, Y.W.; Chun, A.; Cheung, K.; Rashidi, B.; Yang, X.L. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. *J. Biol. Chem.* **2008**, *283*, 5496–5509. [[CrossRef](#)]
209. Zhao, B.; Wei, X.; Li, W.; Udan, R.S.; Yang, Q.; Kim, J.; Xie, J.; Ikenoue, T.; Yu, J.; Li, L.; et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. *Genes Dev.* **2007**, *21*, 2747–2761. [[CrossRef](#)]
210. Gloerich, M.; Ponsioen, B.; Vliem, M.J.; Zhang, Z.C.; Zhao, J.; Kooistra, M.R.; Price, L.S.; Ritsma, L.; Zwartkruis, F.J.; Rehmann, H.; et al. Spatial Regulation of Cyclic AMP-Epac1 Signaling in Cell Adhesion by ERM Proteins. *Mol. Cell. Biol.* **2010**, *30*, 5421–5431. [[CrossRef](#)]
211. Dupont, S.; Morsut, L.; Aragona, M.; Enzo, E.; Giulitti, S.; Cordenonsi, M.; Zanconato, F.; Le Digabel, J.; Forcato, M.; Bicciato, S.; et al. Role of YAP/TAZ in mechanotransduction. *Nature* **2011**, *474*, 179–183. [[CrossRef](#)]
212. Yu, F.X.; Zhao, B.; Panupinthu, N.; Jewell, J.L.; Lian, I.; Wang, L.H.; Zhao, J.G.; Yuan, H.X.; Tumaneng, K.; Li, H.R.; et al. Regulation of the HIPPO-YAP pathway by G-protein-coupled receptor signaling. *Cell* **2012**, *150*, 780–791. [[CrossRef](#)]
213. Fernandez, B.G.; Gaspar, P.; Bras-Pereira, C.; Jezowska, B.; Rebelo, S.R.; Janody, F. Actin-Capping Protein and the Hippo pathway regulate F-actin and tissue growth in Drosophila. *Development* **2011**, *138*, 2337–2346. [[CrossRef](#)] [[PubMed](#)]
214. Wada, K.I.; Itoga, K.; Okano, T.; Yonemura, S.; Sasaki, H. Hippo pathway regulation by cell morphology and stress fibers. *Development* **2011**, *138*, 3907–3914. [[CrossRef](#)] [[PubMed](#)]
215. Wang, X.; Hu, G.; Gao, X.; Wang, Y.; Zhang, W.; Harmon, E.Y.; Zhi, X.; Xu, Z.; Lennartz, M.R.; Barroso, M.; et al. The Induction of Yes-Associated Protein Expression After Arterial Injury Is Crucial for Smooth Muscle Phenotypic Modulation and Neointima Formation. *Arterioscler. Thromb. Vasc. Biol.* **2012**, *32*, 2662–2669. [[CrossRef](#)] [[PubMed](#)]
216. Wang, Y.S.; Cao, W.; Cui, J.J.; Yu, Y.; Zhao, Y.B.; Shi, J.; Wu, J.; Xia, Z.Y.; Yu, B.; Liu, J.J. Arterial Wall Stress Induces Phenotypic Switching of Arterial Smooth Muscle Cells in Vascular Remodeling by Activating the YAP/TAZ Signaling Pathway. *Cell. Physiol. Biochem.* **2018**, *51*, 842–853. [[CrossRef](#)] [[PubMed](#)]
217. Stein, C.; Bardet, A.F.; Roma, G.; Bergling, S.; Clay, I.; Ruchti, A.; Agarinis, C.; Schmelzle, T.; Bouwmeester, T.; Schubeler, D.; et al. YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers. *Plos Genet.* **2015**, *11*. [[CrossRef](#)] [[PubMed](#)]
218. Wang, W.B.; Li, H.P.; Yan, J.; Zhuang, F.; Bao, M.; Liu, J.T.; Qi, Y.X.; Han, Y. CTGF regulates cyclic stretch-induced vascular smooth muscle cell proliferation via microRNA-19b-3p. *Exp. Cell Res.* **2019**, *376*, 77–85. [[CrossRef](#)]
219. Croci, O.; De Fazio, S.; Biagioni, F.; Donato, E.; Caganova, M.; Curti, L.; Doni, M.; Sberna, S.; Aldeghi, D.; Biancotto, C.; et al. Transcriptional integration of mitogenic and mechanical signals by Myc and YAP. *Genes Dev.* **2017**, *31*, 2017–2022. [[CrossRef](#)]

220. Zanconato, F.; Forcato, M.; Battilana, G.; Azzolin, L.; Quaranta, E.; Bodega, B.; Rosato, A.; Bicciato, S.; Cordenonsi, M.; Piccolo, S. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. *Nat. Cell Biol.* **2015**, *17*, 1218–1227. [[CrossRef](#)]
221. Montminy, M.R.; Sevarino, K.A.; Wagner, J.A.; Mandel, G.; Goodman, R.H. Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. *Proc. Natl. Acad. Sci. USA* **1986**, *83*, 6682–6686. [[CrossRef](#)]
222. Gonzalez, G.A.; Montminy, M.R. Cyclic-AMP stimulates somatostatin gene-transcription by phosphorylation of CREB at serine-133. *Cell* **1989**, *59*, 675–680. [[CrossRef](#)]
223. Altarejos, J.Y.; Montminy, M. CREB and the CRTC co-activators: Sensors for hormonal and metabolic signals. *Nat. Rev. Mol. Cell Biol.* **2011**, *12*, 141–151. [[CrossRef](#)] [[PubMed](#)]
224. Gonzalez, G.A.; Menzel, P.; Leonard, J.; Fischer, W.H.; Montminy, M.R. Characterization of motifs which are critical for activity of the cyclic AMP-responsive transcription factor CREB. *Mol. Cell. Biol.* **1991**, *11*, 1306–1312.
225. Chrivia, J.C.; Kwok, R.P.; Lamb, N.; Hagiwara, M.; Montminy, M.R.; Goodman, R.H. Phosphorylated CREB binds specifically to the nuclear protein CBP. *Nature* **1993**, *365*, 855–859. [[CrossRef](#)] [[PubMed](#)]
226. Arias, J.; Alberts, A.S.; Brindle, P.; Claret, F.X.; Smeal, T.; Karin, M.; Feramisco, J.; Montminy, M. ACTIVATION OF CAMP AND MITOGEN RESPONSIVE GENES RELIES ON A COMMON NUCLEAR FACTOR. *Nature* **1994**, *370*, 226–229. [[CrossRef](#)]
227. Kimura, T.E.; Duggirala, A.; Hindmarch, C.C.T.; Hewer, R.C.; Cui, M.Z.; Newby, A.C.; Bond, M. Protein kinase A and EPAC synergistically inhibit Egr1 expression and proliferation in vascular smooth muscle cells. *JMCC* **2014**, *72*, 9–19.
228. Klemm, D.J.; Watson, P.A.; Frid, M.G.; Dempsey, E.C.; Schaack, J.; Colton, L.A.; Nesterova, A.; Stenmark, K.R.; Reusch, J.E.B. cAMP response element-binding protein content is a molecular determinant of smooth muscle cell proliferation and migration. *J. Biol. Chem.* **2001**, *276*, 46132–46141. [[CrossRef](#)]
229. Klemm, D.J.; Majka, S.M.; Crossno, J.T., Jr.; Psilas, J.C.; Reusch, J.E.B.; Garat, C.V. Reduction of Reactive Oxygen Species Prevents Hypoxia-induced CREB Depletion in Pulmonary Artery Smooth Muscle Cells. *J. Cardiovasc. Pharmacol.* **2011**, *58*, 181–191. [[CrossRef](#)]
230. Chen, W.J.; Chen, Y.H.; Lin, K.H.; Ting, C.H.; Yeh, Y.H. Cilostazol Promotes Vascular Smooth Muscles Cell Differentiation Through the cAMP Response Element-Binding Protein-Dependent Pathway. *Arterioscler. Thromb. Vasc. Biol.* **2011**, *31*, 2106–2113. [[CrossRef](#)]
231. Schauer, I.E.; Knaub, L.A.; Lloyd, M.; Watson, P.A.; Gliwa, C.; Lewis, K.E.; Chait, A.; Klemm, D.J.; Gunter, J.M.; Bouchard, R.; et al. CREB Downregulation in Vascular Disease A Common Response to Cardiovascular Risk. *Arterioscler. Thromb. Vasc. Biol.* **2010**, *30*, 733–741. [[CrossRef](#)]
232. Watson, P.A.; Nesterova, A.; Burant, C.F.; Klemm, D.J.; Reusch, J.E.B. Diabetes-related changes in cAMP response element-binding protein content enhance smooth muscle cell proliferation and migration. *J. Biol. Chem.* **2001**, *276*, 46142–46150. [[CrossRef](#)]
233. Molnar, P.; Perrault, R.; Louis, S.; Zahradka, P. The cyclic AMP response element-binding protein (CREB) mediates smooth muscle cell proliferation in response to angiotensin II. *J. Cell Commun. Signal.* **2014**, *8*, 29–37. [[CrossRef](#)]
234. Tokunou, T.; Ichiki, T.; Takeda, K.; Funakoshi, Y.; Iino, N.; Takeshita, A. cAMP response element-binding protein mediates thrombin-induced proliferation of vascular smooth muscle cells. *Arterioscler. Thromb. Vasc. Biol.* **2001**, *21*, 1764–1769. [[CrossRef](#)]
235. Naqvi, S.; Martin, K.J.; Arthur, J.S.C. CREB phosphorylation at Ser(133) regulates transcription via distinct mechanisms downstream of cAMP and MAPK signalling. *Biochem. J.* **2014**, *458*, 469–479. [[CrossRef](#)]
236. Conkright, M.D.; Canettieri, G.; Screaton, R.; Guzman, E.; Miraglia, L.; Hogenesch, J.B.; Montminy, M. TORCs: Transducers of regulated CREB activity. *Mol. Cell* **2003**, *12*, 413–423. [[CrossRef](#)]
237. Purves, G.I.; Kamishima, T.; Davies, L.M.; Quayle, J.M.; Dart, C. Exchange protein activated by cAMP (Epac) mediates cAMP-dependent but protein kinase A-insensitive modulation of vascular ATP-sensitive potassium channels. *J. Physiol.-Lond.* **2009**, *587*, 3639–3650. [[CrossRef](#)]
238. Screaton, R.A.; Conkright, M.D.; Katoh, Y.; Best, J.L.; Canettieri, G.; Jeffries, S.; Guzman, E.; Niessen, S.; Yates, J.R.; Takemori, H.; et al. The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. *Cell* **2004**, *119*, 61–74. [[CrossRef](#)]

239. Shibata, R.; Kai, H.; Seki, Y.; Kato, S.; Morimatsu, M.; Kaibuchi, K.; Imaizumi, T. Role of Rho-associated kinase in neointima formation after vascular injury. *Circulation* **2001**, *103*, 284–289. [[CrossRef](#)]
240. Shibata, R.; Kai, H.; Seki, Y.; Kusaba, K.; Takemiya, K.; Koga, M.; Jalalidin, A.; Tokuda, K.; Tahara, N.; Niiyama, H.; et al. Rho-kinase inhibition reduces neointima formation after vascular injury by enhancing bax expression and apoptosis. *J. Cardiovasc. Pharmacol.* **2003**, *42*, S43–S47. [[CrossRef](#)]
241. Hayashi, K.; Watanabe, B.; Nakagawa, Y.; Minami, S.; Morita, T. RPEL Proteins Are the Molecular Targets for CCG-1423, an Inhibitor of Rho Signaling. *PLoS ONE* **2014**, *9*. [[CrossRef](#)]
242. Smith, S.; Sessions, R.B.; Shoemark, D.; Williams, C.; Ebrahimighaei, R.; McNeil, M.; Crump, M.P.; McKay, T.; Harris, G.; Newby, A.C.; et al. Anti-proliferative and anti-migratory effects of a novel YAP-TEAD interaction inhibitor identified using in silico molecular docking. *J. Med. Chem.* **2019**. [[CrossRef](#)]
243. Liu-Chittenden, Y.; Huang, B.; Shim, J.S.; Chen, Q.; Lee, S.J.; Anders, R.A.; Liu, J.O.; Pan, D.J. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. *Genes Dev.* **2012**, *26*, 1300–1305. [[CrossRef](#)]
244. Wang, C.; Zhu, X.Y.; Feng, W.W.; Yu, Y.H.; Jeong, K.J.; Guo, W.; Lu, Y.L.; Mills, G.B. Verteporfin inhibits YAP function through up-regulating 14-3-3 sigma sequestering YAP in the cytoplasm. *Am. J. Cancer Res.* **2016**, *6*, 27–37.
245. Oku, Y.; Nishiya, N.; Shito, T.; Yamamoto, R.; Yamamoto, Y.; Oyama, C.; Uehara, Y. Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers. *FEBS Open Bio* **2015**, *5*, 542–549. [[CrossRef](#)]
246. Zhang, Z.Z.; Lin, Z.H.; Zhou, Z.; Shen, H.C.; Yan, S.F.; Mayweg, A.V.; Xu, Z.H.; Qin, N.; Wong, J.C.; Zhang, Z.S.; et al. Structure-based design and synthesis of potent cyclic peptides inhibiting the YAP-TEAD protein-protein interaction. *ACS Med. Chem. Lett.* **2014**, *5*, 993–998. [[CrossRef](#)] [[PubMed](#)]
247. Kaan, H.Y.K.; Chan, S.W.; Tan, S.K.J.; Guo, F.S.; Lim, C.J.; Hong, W.J.; Song, H.W. Crystal structure of TAZ-TEAD complex reveals a distinct interaction mode from that of YAP-TEAD complex. *Sci. Rep.* **2017**, *7*. [[CrossRef](#)]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).